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Zusammenfassung 
Rheumatoide Arthritis (RA) und Osteoarthritis (OA) sind die häufigsten muskuloskelettalen 
Erkrankungen (MSD). Beide Krankheitsbilder sind gekennzeichnet durch destruktive 
Veränderungen des Gelenkknorpels und des Knochens. Dies geht einher mit Schmerzen und 
zunehmender Beeinträchtigung alltäglicher Bewegungen. Die Produktion von 
entzündungsfördernden Zytokinen und matrixabbauenden Enzymen durch synoviale Zellen 
löst die Zerstörung von Knorpel und die Aktivierung von Osteoklasten aus. Außerdem wird 
der Aktivierungsstatus von RA synovialen Fibroblasten (RASF) unterstützt, was zur 
Aufrechterhaltung der Entzündung im arthritischen Gelenk führt. Neben Zytokinen sind 
ebenfalls Adipozyten-spezifische Proteine, Adipokine, dafür bekannt, die Expression von 
entzündungsfördernden Zytokinen in RASF zu induzieren. 
Für die Therapie von MSD werden in der Regel entzündungshemmende Medikamente 
eingesetzt. Eine zusätzliche Schmerzlinderung kann durch die Behandlung von Patienten mit 
niedrig dosierter Strahlung erreicht werden. Dabei wird entweder lokale Photonenbestrahlung 
oder eine Ganzkörperbestrahlung mit Radon, angewendet. Die zugrunde liegenden zellulären 
und molekularen Mechanismen der entzündungshemmenden Wirkung von Radon sind 
weitgehend unbekannt.  
In Rahmen dieser Arbeit wurde die Wirkung einer seriellen Radontherapie auf den Adipokin-
Serumspiegel bei Patienten mit MSD (Patientenstudie RAD-ON01) untersucht. Darüber hinaus 
wurde untersucht, ob Röntgenstrahlung die Produktion von Adipokinen durch Adipozyten 
oder die Reaktion von synovialen Fibroblasten auf Adipokin-Behandlung beeinflusst, um zu 
verstehen, ob diese Mechanismen zur Entzündungsmilderung im arthritischen Gelenk führen 
können. Da die Zellen des Fettgewebes, Adipozyten, als Hauptproduzenten von Adipokinen 
beschrieben werden, wurde die Strahlungsantwort von humanen primären subkutanen 
Adipozyten in vitro untersucht. 
In der vorliegenden Arbeit wurde zum ersten Mal eine signifikante Abnahme von Visfatin im 
Serum von MSD-Patienten nach serieller Radonbadbehandlung gezeigt. Darüber hinaus 
wurde eine positive Korrelation zwischen Visfatin-Serumspiegel und Schmerzdauer sowie 
Schmerzintensität festgestellt, was auf eine Hemmung der Entzündungsprozesse hindeutet. 
Außerdem zeigten die in vitro erzielten Ergebnisse, dass Röntgenstrahlung die Adipokin-
induzierte Produktion von entzündungsfördernden und matrixabbauenden Faktoren (IL-6, 
MCP-1, MMP-1) durch RASF reduzieren kann, was potenziell zur Entzündungshemmung 
führt. Weiterhin konnte gezeigt werden, dass Röntgenstrahlung den Differenzierungsprozess 
von Adipozyten und die Adipokin-Produktion nicht beeinflusst, was auf einen relativ 
strahlenresistenten Phänotyp der Fettzellen hinweist. Darüber hinaus legen die in vitro 
Ergebnisse nahe, dass die reifen Adipozyten nicht die Hauptproduzenten von Adipokinen im 
arthritischen Gelenk sind. 
Zusammenfassend wurde in der vorliegenden Arbeit gezeigt, dass die in vitro erzielten 
Ergebnisse mit den in vivo Untersuchungen in Patienten übereinstimmen. Dies weist darauf 
hin, dass ionisierende Strahlung den Entzündungsprozess in den Gelenken von MSD-
Patienten beeinflussen kann. Die Erkenntnisse dieser Arbeit tragen zu einem besseren 
Verständnis von zellulären und molekularen Mechanismen im Zusammenhang mit der niedrig 
dosierten Strahlen- und Radontherapie bei. 
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Abstract 
Rheumatoid arthritis (RA) and osteoarthritis (OA) are the most common musculoskeletal 
diseases (MSD) that affect the joints. Both diseases are characterized by the destructive 
changes of articular cartilage and bone, accompanied by increasing disability and pain. 
Despite the differences in the development of RA and OA, the inflammation process plays a 
decisive role in both cases. The key players in RA are synovial fibroblasts, which gain an 
aggressive behaviour and pro-inflammatory phenotype in the course of disease. The 
production of different pro-inflammatory cytokines and matrix-degrading enzymes by synovial 
cells not only triggers the destruction of cartilage and activation of bone-resorbing osteoclasts, 
but also sustain the activation status of rheumatoid arthritis synovial fibroblasts (RASF), 
contributing to the perpetuation of inflammation in arthritic joint. Besides cytokines, the 
adipokines, mostly produced by adipose tissue, are known to induce the expression of pro-
inflammatory cytokines in RASF.  
Chronic inflammatory diseases are usually treated with anti-inflammatory drugs. Besides 
medications, an additional pain relief is achieved by the treatment of patients with low-dose 
ionizing radiation, either as local photon irradiation or whole-body exposure to radon in 
radon baths or galleries. The anti-inflammatory effects of radon are used in the therapy of 
MSD since many years; however, the underlying cellular and molecular mechanisms are 
widely unknown.  
Therefore, within the scope of this thesis, the effect of a serial radon-bath treatment on 
adipokine serum levels in MSD patients was investigated (RAD-ON01 study). In addition, it 
was examined whether X-ray radiation affects the ability of adipocytes to produce adipokines 
or influences the response of synovial fibroblasts to adipokines, leading to the attenuation of 
inflammation in arthritic joint. 
In the present work, a significant decrease of adipokine visfatin in the serum of MSD patients 
after serial radon-bath treatment is shown for the first time. Furthermore, the positive 
correlation between visfatin serum levels and pain duration as well as pain intensity was 
determined, indicating an attenuation of inflammation. In addition, results obtained in vitro 
demonstrated the ability of X-ray radiation to reduce adipokine-induced production of pro-
inflammatory and matrix-degrading factors (IL-6, MCP-1, MMP-1) by rheumatoid arthritis 
synovial fibroblasts, potentially inhibiting inflammation. Furthermore, the results of the 
present work showed that X-ray irradiation does not affect the differentiation process of 
adipocytes in vitro and their ability to produce adipokines, irrespective of the dose, indicating 
a radiation-resistant phenotype of adipose cells. In addition, the obtained results revealed that 
mature adipocytes are not the main source of adipokines in the arthritic joint. 
Taken together, the results obtained in vitro are consistent with those obtained in vivo, 
indicating that ionizing radiation may affect the inflammation process in joints of MSD 
patients. The findings of this work contribute to a better understanding of cellular and 
molecular mechanisms related to the low-dose radio- (LD-RT) and radon therapy. 
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http://droualb.faculty.mjc.edu/Lecture%20Notes/Unit%202/chapter_8_articulations%20with%20figures.htm 
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1 Introduction 
In the present work, the impact of ionizing radiation on factors related to the changes in bone 
metabolism of patients suffering from musculoskeletal diseases (MSD) was investigated. Basic 
aspects of pathological processes related to MSD are explained in the following chapter. 
Furthermore, a short overview about cells and factors involved in these processes as well as 
about conventional therapies and the use of low-dose radiation in the treatment of MSD 
patients are highlighted in this chapter. 
1.1 Anatomy of knee joints  
The knee joint is the largest and one of the most complex joints in the body. The knee joint 
consist of three main bones: femur, tibia and patella (Fig. 1.1). Bone is a very dynamic organ 
that is continuously modulated. Two cell types are responsible for bone remodeling: bone-
forming osteoblasts and bone-resorbing osteoclasts. Bone is well innervated and vascularized. 
The bone ends are encased with two types of cartilage: articular cartilage and meniscus (Fig. 
1.1). The main function of the cartilage is to provide an even surface for the smooth moving 
of the bones. The only resident cells of cartilage are chondrocytes, which produce a large 
amount of collagenous extracellular matrix (ECM). ECM consists of approximately 80% water 
and 20% different types of collagen and proteoglycans [1]. The cartilage does not contain any 
nerves or blood vessels and is nourished by diffusion from synovial fluid [2]. 
 
 
Fig. 1.1 Anatomy of knee joint (modified according to Courses by Dr. Robert Droual at Modesto J. College1)
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The joint is surrounded by a joint cavity containing the synovial fluid, which enables the 
transport of nutritional substances and oxygen to the different joint tissues and the lubrication 
of articular surfaces [3]. The joint cavity is lined by a synovial membrane, which separates the 
synovial fluid from the joint tissues and supplies the joint with the nutrients (Fig. 1.1). There 
are two cell types of synovial membrane: synovial fibroblasts (SF) or type A cells and 
macrophages or Type B cells.  
Other parts of the joints include ligaments, muscle and fat pads. Ligaments assure the joint 
stability and, together with the meniscus, the protection of articular capsule. Different groups 
of the joint muscles are responsible for the flexibility, extension and stability of the joint. 
Three fat pads were identified in the human knee joint. The infrapatellar fat pad (IPFP) is the 
largest articular fat pad, which is located intra-articular, but extra-synovial (Fig. 1.1). The 
IPFP fills the space behind the patellar tendon and inferior pole of the patella and is a highly 
innervated and vascularized joint tissue (Fig. 1.1) [4]. The physiological role of IPFP is not 
completely understood. However, facilitation of synovial fluid distribution and lubrication of 
knee joint are discussed to be the main functions of IPFP [5], [6].  
1.2 Musculoskeletal diseases  
Musculoskeletal diseases represent the highest cause of disability in Europe, and affect 
millions of people around the world [7]. They include degenerative and chronic inflammatory 
joint diseases (osteoarthritis, rheumatoid arthritis) and other bone diseases (osteoporosis). 
The majority of MSD is associated with chronic pain, joint damage and reducing mobility of 
patients. Rheumatoid arthritis (RA) and osteoarthritis (OA) are the most common MSD. 
Although the degradation of cartilage and bone, accompanied by intense pain and 
deformation of the joints, are common for both diseases, the pathogeneses of RA and OA are 
different. While typical changes occurring in the course of RA are caused by chronic 
inflammation, OA is considered as primary degenerative joint disease; the inflammation in 
case of OA is considered as a secondary course for disease development [8], [9]. Nevertheless, 
the underlying mechanisms of both RA and OA are not completely clarified. The development 
of both diseases is explained in detail below. 
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease, which is 
associated with progressive disability, systemic complications and even death [10]. The 
disease is characterized by synovial inflammation, hyperplasia, cell activation and invasive 
growth of synovium into cartilage, leading to joint destruction [11]. Although the exact cause 
of RA is still unknown, recent studies suggest that immune regulatory factors are involved in 
the disease [10], [12]. Thus, in previously published studies it was shown that more than 
80% of patients suffering from RA carry the epitope of the HLA-DRB1*04 cluster [12]–[14]. 
These RA-associated HLA-DRB1 alleles encode in one of their hypervariable regions for an 
amino acid motif, which is known as a "shared epitope". The function of the HLA class II 
molecules is to present the antigens to T helper cells, which initiate an immune response. This 
leads to the activation of T-cells with subsequent production of disease-related pro-
inflammatory cytokines. How the formation of RA is promoted by the "shared epitope" of the 
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HLA-DRB1 allele is not known [13], [15]. Additionally, the environmental factors such as 
smoking or infections could influence the development and severity of disease [16], [17]. 
A variety of different cell types, including synovial fibroblasts, macrophages, T cells and B 
cells, contributes to the inflammatory and destructive processes in RA [18]. Typical symptoms 
of RA such as chronic inflamed synovium, joint swelling and pain are the consequences of 
changed behaviour of synovia cells. The resulting joint damage usually occurs in the first year 
after disease outbreak and increased in course of disease [19]. 
Osteoarthritis 
In contrast to RA, osteoarthritis (OA) is considered as primary degenerative joint disease. 
Although the initiating factors in OA are still unknown, an important role is attributed to the 
mechanical factors such as overweight or overuse; however, also genetic factors may 
contribute to the development of disease [8], [20]. Affected patients exhibit similar symptoms 
as RA patients, such as swelling joints, pain and reduced mobility. 
The cartilage damage in OA is mediated by an increased release of matrix-degrading 
metalloproteases (MMPs), which are produced by chondrocytes [8], [21]. Chondrocytes are 
the only one cell type, residing in adult articular cartilage, and are capable to respond to any 
changes in surrounding conditions [8], [22]. In OA, this response is characterized by forming 
of chondrocyte clusters and hypertrophic proliferation. In the further course of the disease, 
the changes in composition and structure of the cartilage lead to an increased production of 
MMPs and other factors involved in cartilage degradation. As a consequence of disrupted 
cartilage integrity, the apoptosis rate of chondrocytes increased, resulting in the development 
of empty lacunas [23].  
Although OA is described as a “non-inflammatory” disease, inflammation does play a role in 
the pathogenesis of this disease [3]. The increased level of pro-inflammatory cytokines in 
synovial fluid of the OA patients was reported in many studies [9], [24], [25]. In addition, it 
was shown that chondrocytes and osteoarthritic synovial fibroblasts (OASF) strongly respond 
to a stimulation with cytokines and adipokines by increasing production of MMPs [9], [26], 
[27]. Furthermore, it is known that chondrocytes support osteoclastogenesis by receptor 
activator of NF-kB ligand (RANKL) production [22], [28]. Thus, OA is a much more complex 
disease than “wear and tear” disorder. However, the question whether inflammation is a main 
trigger or a secondary cause of OA is still under investigation [8]. 
1.3 Role of synovial fibroblasts in musculoskeletal diseases  
Synovial fibroblasts (also called fibroblast-like synoviocytes, SF) are cells of mesenchymal 
origin, and together with synovial macrophages are residing in synovial membrane [29]. In 
healthy joints, the physiological function of SF is the maintenance of matrix remodeling and 
supply of joint cavity with nutritive proteins and lubricating molecules such as hyaluronic acid 
and lubricin [29], [30]. In healthy individuals consisting of 1-3 layers of synovial fibroblasts, 
the synovial membrane becomes thickened under pathological conditions in RA and OA. 
Inflammation in the synovium is accompanied by infiltration of immune cells and aggressive 
proliferation of SF, leading to the hyperplasia of the synovial membrane. Although the 
inflammation in RA joints is more intense than in OA, typical inflammation-related changes of 
SF are present in both diseases [8], [31]. Since in the present work the synovial fibroblasts of 
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rheumatoid arthritis patients (RASF) were used as an investigation model, the pathogenic 
changes in these cells are described in detail below. 
RASF in RA synovium possess an unique aggressive phenotype, which is a consequence of 
persistent cell activation [32], [33]. Multiple factors contribute to the activation of RASF (Fig. 
1.2). However, the exact mechanisms are still unknown. Once activated, RASF actively 
participate in inflammation and cartilage destruction by secretion of pro-inflammatory 
cytokines (IL-6, IL-8, MCP-1), matrix-degrading enzymes (MMP-1, MMP-9), osteoclasts-
activating factors (RANKL) and adhesion molecules (ICAM, VCAM) (Fig. 1.2) [32], [34], 
[35]. The latter are important for attachment to cartilage and invasion. Concurrently, the 
destruction of cartilage is assisted by increased secretion of MMPs. In addition, RASF 
contribute directly to the bone resorption via production of cathepsin K and L, enzymes 
involved in the degradation of collagens type I, II, IX, XI and proteoglycans [29], [36]. 
Moreover, RASF exhibit uncontrolled proliferation, lack of apoptosis and high migration 
potential. Both, reduced apoptosis and increased proliferation, lead to synovial hyperplasia, 
which induces the development of hypoxic conditions [37]. Local hypoxia induces 
proangiogenic and chemotactic factors in RASF, leading to the neoangiogenesis. This in turn 
contributes to the increased infiltration of immune cells in the joint. In addition, hypoxia 
increased unique long-distance migration potential of RASF, causing spreading of RA-
mediated erosion and inflammation to the unaffected joints [37], [38].  
Thus, synovial fibroblasts are the key effector cells in the development of RA. Targeting their 
aggressive destructive and inflammatory properties is a main task for the development of joint 
protective therapy of RA [37], [39]. 
 
Fig. 1.2 Activating factors and contribution of RASF to the joint destruction in RA. Data from [8], [29], [39]  
1.4 Role of adipose tissue in musculoskeletal diseases  
Adipose tissue 
Adipose tissue is a loose connective tissue with a primary role to store energy. However, 
recently, adipose tissue was discussed as an important endocrine organ, which is involved in 
the mediation of immune and inflammatory response [40]. Two types of adipose tissue are 
known: the white adipose tissue (WAT) and the brown adipose tissue, which have different 
functions and cellular composition [41]. In the present work, the cells of WAT were used as 
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an investigation model. Therefore, an overview about the main functions of WAT in 
physiological and pathological processes will be given below. 
The adipose tissue produces several factors, which influence different biological processes, 
including energy homeostasis (lipid metabolism, insulin sensitivity, appetite, etc.), immune 
response, reproductive function, blood pressure and angiogenesis [42], [43]. The disturbance 
of the fine regulation of endocrine functions of adipose tissue leads to the chain reaction of 
pathological changes in cell composition as well as in expression and secretion of adipose 
tissue-specific factors. Altered secretion of adipokines, for instance, leads to the development 
of metabolic, cardiovascular, inflammatory and mammalian diseases [44]. The increased 
production of pro-inflammatory cytokines results in a chronic low-grade inflammation of 
adipose tissue. Inflamed fat tissue in turn can promote systemic inflammation and insulin 
resistance. Both insulin resistance and dysregulation of key adipokines represent a core of 
systemic metabolic disorders with a developing of various diseases as a consequence [45].  
Metabolic syndrome (MS) is a group of risk factors for developing cardiovascular diseases 
(CVD), diabetes, etc. As mentioned above, the insulin resistance and the characteristic 
adipokine profile are the key components of MS. Moreover, body weight changes and 
increased blood pressure are associated with the development of MS [46], [47]. Several 
musculoskeletal diseases, including RA and OA, are associated with an increased prevalence 
of CVD [11], [48]. Many studies showed the occurrence of most components of MS in RA 
patients [49]. The relationship between adipose tissue, inflammation, metabolic syndrome 
and CVD is very complex. There is growing evidence that a changed secretome of adipose 
cells and a local inflammation within adipose tissue are the main contributors to insulin 
resistance and systemic inflammation, the main features of MS. However, the induction factor 
that caused these dramatic changes in adipose tissue remains unknown [50]. 
Infrapatellar fat pad 
WAT is distributed throughout the body in several depots, which differ in their structural 
composition and biological function [51], [52]. The most widely investigated depots are 
subcutaneous (SAT) and visceral (VAT) fat tissues. Although it is known that adipose tissue 
produces a variety of inflammatory mediators, which can contribute to the destruction of 
cartilage and bone, the knowledge about one of the adipose tissue depots – infrapatellar fat 
pad (IPFP) – is still very limited [6]. The special location of IPFP, close to the synovial 
membrane and cartilage, has a special significance in musculoskeletal diseases, such as OA 
and RA.  
Like all adipose tissue depots, IPFP is an endocrine organ, which secretes a variety of 
cytokines and adipokines [53]. It is very likely that the IPFP undergoes a series of cellular and 
molecular changes under pathological conditions such as inflammation. The increased 
production of IL-6, IL-8, TNFα as well as adipokines adiponectin, leptin and visfatin by IPFP in 
response to inflammatory stimuli was described in many studies [6], [54], [55]. The 
enhanced concentrations of these cytokines and adipokines were found in the synovial fluid of 
patients with MSD. Besides cytokines and adipokines, IPFP also secretes a large amount of 
lipids, whose primary function is to store and release energy [56]. However, a study of 
Gierman et al showed that the IPFP of OA patients exhibit more pro-inflammatory lipid profile 
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than IPFP from healthy donors [57]. In addition, a larger IPFP volume in patients with OA 
compared to healthy individuals was associated with more pronounced pain, suggesting that 
the IPFP could be a source of knee pain in patients with MSD [4].  
Adipose tissue, including IPFP, consists to a larger extent of adipocytes. Other cell types of 
adipose tissue, called stromal vascular fraction (SVF), are stem cells, macrophages, 
lymphocytes, fibroblasts and endothelial cells. The balance between different cell types within 
adipose tissue is variable and depends on both location of the adipose tissue depot and  
surrounding conditions [56], [58], [59]. Since the crosstalk between IPFP and other tissues in 
the joint is known, an exposure to chronic inflammation under pathological conditions might 
induce the infiltration of immune cells, leading to inflammation of adipose tissue [54]. 
Considering the location of IPFP adjacent to the synovial membrane, it is conceivable that the 
inflammation-induced production of IPFP-secreted factors contributes to the perpetuation of 
inflammation and activation of SF in arthritic joint [53] (Fig. 1.3).  
 
 
Fig. 1.3 Infrapatellar fat pad as a source of several pro-inflammatory factors. Modified according to [56] 
Adipocytes 
As mentioned above, adipocytes are the main cell type of adipose tissue. They differentiate 
from pluripotent mesenchymal stem cells and are primary responsible for the energy storage 
in form of triglycerides in their cellular lipid droplets [60]. However, adipocytes are now 
recognized as highly active secretory cells that play a role in whole body homeostasis, 
including inflammatory and immune responses [45], [61]. Adipocytes are major producers of 
adipokines such as adiponectin, leptin, visfatin and resistin. In addition, they secrete various 
pro-inflammatory cytokines, including IL-6, IL-8 and TNFα [62]. Under inflammatory 
conditions, the changes in the adipocyte metabolism initiate alterations in adipose tissue, 
leading to immune cell infiltration and increased production of pro-inflammatory factors, 
including adipokines [44], [60]. 
The differentiation process of adipocytes is complex and includes different steps of 
commitment, cell contact, mitosis, clonal expansion, growth arrest and maturation (Fig. 1.4) 
[43]. Although the cells undergo many steps on the way to mature adipocyte, the process can 
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be divided into two phases [63]. In the first phase – determination – the cell morphology does 
not change, but the pre-adipocytes loose the potential to differentiate into other cells [63]. 
The molecular mechanisms underlying this process are widely unknown [43]. In the second 
phase, called terminal determination, the pre-adipocytes acquire properties of mature 
adipocytes. The molecular mechanisms during this phase are characterized by a highly 
regulated interplay of stimulatory and inhibitory transcription factors [43], [63].  
The critical factors for the complete and seamless adipocyte development are the peroxisome-
proliferator-activated receptor gamma (PPARγ) and the CCAAT-enhancer-binding proteins 
(C/EBPs) [61], [63]. Hormones like insulin and glucocorticoids or isobutyl-methyl-xanthine 
(IBMX) trigger adipogenic differentiation by induction of C/EBPß and C/EBPγ. These in turn 
activate two isoforms of PPARγ, PPARγ1 and PPARγ2 as well as many other adipogenic genes. 
Upon ligand activation, PPARγ together with C/EBPα leads to the complete differentiation 
into mature adipocytes [61]. PPARγ is the key transcription factor, which is sole sufficient for 
adipogenesis. It was shown that only the presence of PPARγ is sufficient to induce adipocyte 
differentiation, but the differentiation cannot be induced in absence of PPARγ [63], [64]. At 
the late stages of differentiation, the adipocytes increase lipid accumulation and acquire 
sensitivity to insulin. In addition, the expression of late differentiation markers such as 
glucose transporter 4 (GLUT4), leptin, adiponectin and visfatin occurs (Fig. 1.4) [61]. 
 
 
Fig. 1.4 Differentiation process of adipocytes. Cell development stages and gene expression in course of 
differentiation from MSC to mature adipocyte. Modified according to [43] 
SGBS cells 
Human primary adipocytes are widely used to investigate differentiation and metabolism of 
the fat cells. However, the usage of primary material is often associated with some limitations. 
The variations between donors and the isolation of the cells from different adipose tissue 
depots lead to different results and large variations in the studies and render the 
characterization of the cells more difficult. In addition, primary pre-adipocytes have a limited 
capacity for differentiation. Therefore, the different cell culture models were established in 
the past years. However, these investigation models are to a large extent of animal origin. 
Since it is known that the cellular composition and function of adipose tissue differ between 
species, the animal adipocyte models are not sufficient for investigation on human fat biology 
[65]. 
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Due to mentioned limitations, the experiments of the present work were mostly performed 
with cells isolated from the subcutaneous fat tissue of a patient with Simpson-Golabi-Behmel 
syndrome (SGBS). The SGBS is a rare X-linked disorder, which is associated with pre- and 
postnatal overgrowth and increased risk of embryonal cancer [65], [66]. Although a mutation 
in Glypican 3 gene, which is known to be involved in the control of organ growth, is 
considered to be associated with this disease, the exact mechanism causing SGBS is not yet 
known [65]. The cell strain isolated from the subcutaneous adipose tissue of an infant with 
SGBS exhibit a high capacity for adipocyte differentiation. In addition, the morphology, the 
gene expression pattern and the biochemical function are very similar to that of human 
primary adipocytes [66], [67]. SGBS cells provide therefore an appropriate model for studies 
on various aspects of human adipose tissue [68]. However, it should be noted that the cells 
are obtained from the patient with a not characterized gene mutation, which could have an 
influence on some aspects of adipocyte biology [66]. 
1.5 Factors involved in the pathogenesis of musculoskeletal diseases 
The production of various pro-inflammatory factors including cytokines, matrix-degrading 
enzymes and adipokines plays a central role in the pathogenesis of MSD [10]. The 
inflammatory process is accompanied by an increased secretion of cytokines such as IL-6, IL-8, 
TNFα, MCP-1 and IL-1ß. Furthermore, changes in the adipocyte metabolism lead to the 
altered production of adipokines such as visfatin, adiponectin, leptin and resistin [69]. The 
adipokines in turn induce the expression of pro-inflammatory cytokines and matrix-metal-
proteinases in other cells of synovium, including synovial fibroblasts, chondrocytes and 
immune cells. This leads to perpetuation of inflammation and joint destruction. The key 
functions of pro-inflammatory factors involved in the pathogenesis of RA and OA are 
described below. 
1.5.1 Cytokines 
Cytokines are glycoproteins, which are responsible for the communication between immune 
cells [70]. Increased levels of cytokines such as IL-6, IL-8 and TNFα in serum and synovial 
fluid of patients with MSD were found to correlate with disease activity, radiographic joint 
damage and pain intensity [26], [70], [71]. Furthermore, the pro-inflammatory cytokines 
upregulate the expression of matrix-degrading and osteoclasts-activating factors and stimulate 
the production of reactive oxygen species (ROS), contributing to the disease progression [70], 
[72].  
Interleukin 6 (IL-6) is one of the key cytokines involved in the pathogenesis of rheumatoid 
arthritis (RA) [10]. IL-6 drives the activation of local leukocytes, endothelial cells and synovial 
fibroblasts by inducing the production of various pro-inflammatory factors [10]. In addition, 
IL-6 upregulates the expression of MMP-1, MMP-3 and MMP-13 in chondrocytes, leading to 
cartilage destruction [26]. IL-6 also mediates systemic effects, which promote cognitive 
dysfunction and dysregulation of lipid and glucose metabolism, in particular insulin sensitivity 
and fatty acids oxidation [10], [73], [74]. Since the elevated circulating levels of IL-6 are 
associated not only with inflammation, but also with an increased risk of coronary artery 
disease (CAD) [73], the involvement of IL-6 in metabolic syndrome is conceivable. IL-6 is a 
cytokine, which is produced by a variety of different cell types. However, approximately 30% 
of circulating IL-6 is produced by adipose tissue [73].  
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Similar to IL-6, tumor necrosis factor alpha (TNFα) and interleukin 1 beta (IL-1ß) play the 
pivotal roles in the pathogenesis of rheumatoid arthritis. Both cytokines are produced by a 
variety of synovial cells, including synovial fibroblasts and immune cells [75]. TNFα and IL-1ß 
stimulate their own production and promote inflammation and cartilage destruction by 
inducing different pro-inflammatory cytokines, matrix-degrading factors and adhesion 
molecules in synovial cells [72]. In addition, TNFα directly mediates chemokine expression, 
adhesion and angiogenesis. Moreover, TNFα together with RANKL contributes to 
osteoclastogenesis [76].  
The accumulation of immune cells in arthritic synovium is a hallmark for acute inflammation. 
Interleukin 8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) are the most important 
cytokines that mediate chemotaxis in arthritic joint [77]. IL-8 as a neutrophil chemoattractant 
is responsible for the increased number of neutrophils at the side of inflammation and is 
associated with joint swell and pain [77]. Beside chemotaxis, IL-8 stimulates both osteoclasts 
formation and activity, leading to the bone resorption [78]. The role of MCP-1 in MSD is the 
chemoattraction of macrophages in inflamed joint [77]. In addition, increased MCP-1 level 
causes insulin resistance in adipocytes and monocytes, leading to the development of 
metabolic disorders [69], [79]. Furthermore, both chemokines IL-8 and MCP-1 induce the 
formation of new blood vessels in arthritic synovium and are, therefore, important promoters 
of angiogenesis [77]. 
1.5.2 Matrix-degrading enzymes 
The highly inflammatory microenvironment of arthritic synovium stimulates the synovial 
fibroblasts and chondrocytes to produce matrix metalloproteinases MMP-1, MMP-3, MMP-9 
MMP-13 as well as cathepsins, the prominent mediators of cartilage and bone degradation 
[8], [80]. Collagenases MMP-1 and MMP-13 are responsible for the initial cleavage of 
collagens. MMP-1 is mostly produced by synovial fibroblasts, and MMP-13 – by chondrocytes. 
Besides collagen, MMP-13 cleaves aggrecan, a critical component of cartilage structure [81]. 
Other matrix enzymes such as MMP-3 (stromelysin 1) and MMP-9 (gelatinase B) degrade the 
fragments, remaining after initial collagen cleavage [10], [31]. Among them, cathepsins B, K 
and L are considered to be the main proteases in the degradation of bone matrix [82]. 
Cathepsins B and K degrade collagen types I and IV as well as fibronectin, whereas cathepsin 
L is responsible for cleavage of collagen types I, II, IX and XI, mediating both cartilage and 
bone destruction [36], [83]. The main producers of cathepsins in arthritic joint are synovial 
fibroblasts and osteoclasts [82], [83]. 
1.5.3 Adipokines 
Adipokines are cytokine-like molecules, primarily produced by adipose tissue. They modulate 
a broad spectrum of physiological and pathophysiological processes, ranging from regulation 
of appetite and insulin sensitivity to inflammation and immune response [41], [84]. 
Imbalance in adipokine profile leads to changes in the metabolism of adipocytes and the 
whole adipose tissue, resulting in development of metabolic and other diseases as a 
consequence [45], [85]. Elevated levels of adipokines were detected in serum and synovial 
fluid of MSD patients [86]–[89]. In MSD, adipokines are considered to be the emerging 
modulators of inflammation and joint destruction, as they induce the production of a variety 
of pro-inflammatory cytokines, matrix-degrading and osteoclasts-activating factors in different 
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synovial cells [90]. The most investigated adipokines are adiponectin, visfatin, leptin and 
resistin [86]. 
Visfatin 
Visfatin is an adipokine, mostly, but not exclusively produced by adipose tissue. Visfatin, also 
called nicotinamide phosphoribosyl transferase (NAMT), plays an important role in the 
regulation of many cellular processes because of its involvement in NAD synthesis [91], [92]. 
In degenerative joint diseases such as RA and OA, serum and synovial fluid levels of visfatin 
are elevated and correlate with degree of inflammation and disease activity [93], [94]. 
Visfatin promotes cytokine synthesis and increases motility of synovial fibroblasts, 
contributing to the synovial inflammation and spreading the disease to healthy joints [95], 
[96]. Moreover, visfatin contributes to vascular inflammation by inducing the production of 
pro-inflammatory cytokines by peripheral mononuclear cells and promoting macrophages 
survival [97], [98]. In addition, visfatin upregulates the expression and activity of MMPs and 
downregulates the expression of MMP-inhibitors, contributing to cartilage degradation [99]. 
Visfatin is considered to be a potential target for the therapy of RA and OA. 
Adiponectin 
Adiponectin is another well-studied adipokine, predominantly secreted by mature adipocytes 
[84], [86]. Besides its multiple functions in energy metabolism, adiponectin plays a role in 
bone metabolism, cardiovascular and immune systems [84], [100]. Although adiponectin was 
widely investigated in the last years, its specific functions in different physiological and 
pathological processes remain unclear. Several studies reported an anti-inflammatory and 
protective effects in obesity-related and vascular diseases [101]–[103]. By contrast, in 
degenerative joint diseases such as OA and RA, adiponectin supports inflammatory and 
matrix-degrading processes [100], [101]. Adiponectin was reported to induce the production 
of pro-inflammatory (IL-6, IL-8) and matrix-degrading (MMP-1, MMP-3) factors in synovial 
fibroblasts [27] and chondrocytes [104]–[107]. In addition, adiponectin contributes to 
leucocyte and monocyte infiltration by inducing the expression of adhesion molecules (VCAM-
1) and chemoattractant factors (MCP-1) in chondrocytes [11], [108]. High serum and 
articular adiponectin levels are associated with the radiographic changes in patients with RA 
[27]. In addition, the synovial fluid level of adiponectin positively correlates with 
degenerative fragments of aggrecan in affected joints of patients with OA, suggesting its 
potential as a marker for disease progression [27], [86]. However, the findings about the 
association of adiponectin with clinical parameters such as disease severity or pain are 
contradictory [109]. The discrepancies between studies are more likely related to the different 
isoforms of adiponectin. In serum, adiponectin exists in three different forms – low molecular 
weight (LMW), middle molecular weight (MMW) and high molecular weight (HMW) – that 
differ in their biological activity [110], [111]. It was shown that HMW/MMW adiponectins 
have more pronounced pro-inflammatory effect on the synovial cells [111]–[113]. Many 
studies suggest adiponectin as an important target for the treatment of MSD. However, more 
research in this field is required to fully elucidate the function of this adipokine [114].  
Leptin 
Leptin is one of the most important adipokines, produced by adipose tissue. The main 
function of leptin is the regulation of body weight by inhibition of food intake and stimulation 
of energy expenditure [115]. Apart from this, leptin is involved in a variety of biological 
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processes such as glucose and lipid metabolism, blood pressure, reproduction, T cell function 
and bone metabolism [116], [117]. Several studies reported a close correlation between 
leptin levels and risk of aggressive course of RA [90], [118]. Leptin levels are elevated in 
serum and synovial fluid of MSD patients. Furthermore, leptin is known to induce IL-6 and IL-
8 in synovial fibroblasts as well as IL-8 and adhesion molecules (VCAM-1) in chondrocytes 
[86], [106], [108]. In addition, leptin was shown to modulate the T-cell balance by driving T 
cell differentiation towards Th1 cells, exerting pro-inflammatory properties [101], [116], 
[119]. In OA, leptin is able to increase the production of osteoprotegerin (OPG) in monocytes 
and osteoblasts, promoting formation of osteophytes [86]. Although leptin is considered as an 
important target for therapy of MSD, current biological therapies such as TNFα-inhibitors do 
not affect leptin levels [90]. 
Resistin 
Resistin is an adipocyte-derived adipokine with an important role in inflammation [120]. The 
known physiological functions of resistin are the regulation of metabolic and inflammatory 
processes as well as adipogenesis [114], [121]. High levels of resistin were found in serum 
and synovial fluid of RA and OA patients. In addition, resistin levels positively correlate with 
several markers of inflammation such as C-reactive protein (CRP), erythrocyte sedimentation 
rate (ESR) and TNFα [86], [120], [122]. Expression of resistin in peripheral blood 
mononuclear cells (PBMC) is upregulated by the pro-inflammatory cytokines IL-6, IL-1ß and 
TNFα. In turn, resistin induces the production of IL-6 and TNFα in macrophages [86], [123]. 
Moreover, the inhibition of TNFα in patients with RA results in a significant decrease of serum 
resistin levels in association with a reduced CRP level [86], [120]. Based on this, resistin is 
proposed as an important molecule in NF-kB activation and cytokine production by PBMC 
[120]. 
1.6 Therapy of musculoskeletal diseases 
The most important goals for the treatment of patients suffering from musculoskeletal 
diseases (MSD) are to relieve pain, to stop or slow down inflammation and joint damage, and 
to improve joint mobility. Treatment of MSD includes usually medications, physical therapy 
and regular exercises. In addition, low-dose irradiation is used for the treatment of MSD.  
1.6.1 Conventional medical treatment 
In recent years, the prognosis for MSD patients has dramatically improved. The reason for 
that is the better understanding of disease pathogenesis and, therefore, the development of 
biologic therapies and the use of different treatment possibilities in combination [124]. There 
is a variety of medications for the treatment of MSD. Usually the disease-modifying-anti-
rheumatic/osteoarthritic drugs (DMARDs/DMAODs) and the non-steroidal anti-inflammatory 
drugs (NSAIDs) are used for the treatment of MSD patients. NSAIDs reduce pain and 
inflammation by blocking cyclooxygenases (COX), which are associated with inflammation in 
arthritic joints [125]. DMARDs are used to control disease and to limit joint damage, resulting 
in the improved long-term outcome.  
The important targets for medical therapy of MSD are cytokines, such as TNFα, IL-1ß and IL-
6, which induce inflammation and contribute to joint destruction. Apart from them, also 
adipokines are in the focus of drug development, as they induce the production-of pro-
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inflammatory cytokines in the joint. Recently, a variety of TNFα-blocking drugs were 
developed, while targeting of IL-1ß is still a challenge. Anakinra is the only approved 
antagonist for IL-1-receptor, which binds IL-1ß and, in the combination with methotrexate 
(MTX), provides significantly better clinical benefit than MTX alone [126]. Also an 
administration of tocilizumab, an antibody directed against IL-6, in combination with MTX 
results in the disease remission in approximately 30% of patients [127].  
Bisphosphonates represent another drug class, which is successfully used in the therapy of 
MSD. Bisphosphonates are powerful inhibitors of bone resorption and are mostly used in the 
treatment of osteoporosis and OA [3], [128]. In their mechanism of action, bisphosphonates 
are internalized by osteoclasts at sites of bone resorption, leading to the disturbance of their 
cellular metabolism and finally to the apoptosis of osteoclasts [128], [129].  
Although drug therapies are shown to be useful in different MSD and are often well tolerated 
by patients, adverse side effects (Tab. 1.1) often cannot be predicted. In addition, high costs 
and inconvenience of intravenous administration give an impetus for developing of new 
therapeutic possibilities [130]. 
Drug Target Side effects 
Tocilizumab IL-6 Infections, cardiac events, non-melanoma skin tumors, 
hematological disturbances   
Rituximab CD-20 
protein 
Severe infusion reactions, cardiac events 
Anakinra IL-1 Severe infusion reactions, headache, abdominal pain 
Infliximab 
Adalimumab TNFα Increased risk for tuberculosis, infections, neutropenia, 
headache 
Bisphosphonates osteoclasts Severe musculoskeletal pain, hypocalcemia, ocular 
inflammation, osteonecrosis  
Tab. 1.1 Selected drugs for the therapy of MSD and their side effects. Data from [126], [130]–[132] 
1.6.2 Low-dose radiotherapy 
In addition to medical treatment, patients with several MSD can benefit from the application 
of low-dose ionizing radiation. There are two types of radiotherapy available: patients are 
exposed either locally (photon irradiation, LD-RTp) or they receive a whole-body irradiation in 
radon galleries or radon baths (LD-RTradon). LD-RT represents an effective and inexpensive 
alternative to the drug treatment. Although the risk for the side effects of LD-RT is low, 
radiation exposure is not recommended for younger patients and pregnant women, because of 
the risk for possible tumor induction as a long-term effect [133]. 
Photon irradiation is usually given in a fractionated regimen with a total dose of 6 Gy. The 
single dose is adjusted in consideration to the type and phase of disease, and is normally 0.5-1 
Gy [133]. The largest group of patients, benefiting from LD-RTp, are patients, suffering from 
degenerative joint disorders [133]. Clinical studies demonstrate significant pain relief and 
improved joint mobility in patients after LD-RTp. However, the molecular and cellular 
mechanisms, underlying clinical effects, are not widely investigated. Several studies showed 
in animal models that low-dose ionizing radiation attenuate inflammation, leading to the 
improvement of clinical symptoms [134], [135]. The effects of low-dose radiation such as 
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reduction of pro-inflammatory cytokines (IL-6, TNFα), decrease in reactive oxygen species 
(ROS) and nitric oxide (NO), reduced infiltration of macrophages and increase in regulatory 
T-cell population were shown by a number of authors [135]–[138]. These findings suggest 
that low-dose ionizing radiation enhances immune functions and affects the signaling 
processes and cells involved in the development of inflammation [137].  
In addition to LD-RTp, radon treatment is used for the therapy of MSD. Low doses (0.2-0.5 
mSv) of alpha radiation emitted by a noble gas radon (Rn-222) can be applied either in form 
of whole-body irradiation in radon galleries (radon concentration 20-160 kBq/m3) or radon-
enriched baths (radon concentration 0.3-3 kBq/L) [139]. The patients receive usually a series 
of 8-12 administrations, 20-60 min each [140], [141]. The penetration ability of alpha-
particles is between 20 and 40 µm (water/tissue), and the residence time of radon in body is 
very short – about 15-30 min [142]. The investigations of radon solubility in different organs 
showed that the adipose tissue may be a major reservoir of radon [143], [144]. The estimated 
alpha dose given to the fat tissue after radon irradiation is much higher than to other organs 
[145]. 
LD-RTradon has been reported to improve mobility of joints and to reduce pain and 
inflammation in patients with MSD [140], [146]. Although some clinical studies related to 
radon exposure were performed, underlying mechanisms are still widely unknown. However, 
Lange et al reported an increase in bone-forming factors (OPG) and decrease in bone-
resorbing (RANKL) and inflammatory (TNFα) factors in patients after LD-RTradon [141]. Also 
the decrease of anti-CCP antibodies (ACCP), which is close related to the bone destruction in 
RA, was shown in patients received LD-RTradon [141], [146]. In addition, Rühle et al showed 
that LD-RTradon caused immune modulations in peripheral blood of MSD patients, probably 
leading to the attenuation of inflammation [140]. The first findings on cellular and molecular 
levels indicate the ability of LD-RTradon to influence osteo-immunological mechanisms, leading 
to the beneficial effects, such as improved joint mobility, pain relief and attenuation of 
inflammation. Combination of LD-RTradon with physical exercises may even enhance the 
mobility improvement of MSD patients [142], [147]. 
1.7 Physical characteristics of ionizing radiation 
Both photons (X-rays) and alpha particles (radon), discussed in the present work, are types of 
ionizing radiation. Ionizing radiation is a form of radiation with enough energy to remove 
electrons from atoms or molecules. The released energy (∆Eabs) per unit mass (∆m) is the 
dose (D), an important physical parameter for describing biological effects of ionizing 
radiation: 
𝐷 =
∆Eabs
∆m
 [𝐺𝑦 =
𝐽
𝑘𝑔
] 
When ionizing particles pass through the matter, they lose energy along the length of their 
track. The density of energy deposition in matter is called Linear Energy Transfer (LET). The 
LET depends on the type of radiation and is described as an energy loss (∆E) per unit distance 
covered by the particle(∆ds): 
𝐿𝐸𝑇 =
∆E
∆ds
 [
𝑘𝑒𝑉
µ𝑚
] 
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Radiation with LET < 10 keV/µm is designated as sparsely ionizing radiation, and radiation 
with higher LET – as densely ionizing radiation. 
The photon radiation (X-rays) is sparsely ionizing radiation. Photons interact with matter via 
photo- and Compton-effect. Free electrons, generated by ionization, transmit their energy to 
other electrons and ensure homogeneous dose distribution (Fig. 1.5). The energy deposition 
of photons decreases with increasing penetration depth.  
Alpha particles, emitted by radon, are densely ionizing. The microscopic dose deposition 
pattern in this case is heterogeneous (Fig. 1.5). The probability for a cell to be traversed by 
one alpha particle is Poisson-distributed. At low doses, a fraction of cells does not receive 
radiation at all. Also, alpha particles have a very shot penetration ability, which depends on 
material density.  
 
Fig. 1.5 Microscopic dose deposition of sparsely (X-ray) and densely (carbon ions) ionizing radiation. Presented 
are dose distributions of 2 Gy on the mammalian cell nuclei (modified according to [148] 
The alpha-emitter radon (Rn-222) is a noble gas, which occurs naturally as a part of the 
radioactive decay chain of uranium. It has a half-life time of 3.8 days and is produced by an 
alpha decay of Rn-226 (Fig. 1.6). The total decay energy of radon and its decay products is 
approximately 19.2 MeV, and is mostly delivered by alpha-particles [149], [150]. Radon is 
incorporated via the epithelium tissues of lung and skin and remains in the body 
approximately 30 min [142]. Since radon is a noble gas, chemical reactions within the body 
do not occur. The energy deposition can have a biological effect.  
 
Fig. 1.6 Uranium decay chain. Adopted from [151] 
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1.8 Radiation biology  
Radiation causes a variety of biochemical and biological alterations in biological matter such 
as cells or tissues. The most radiosensitive target is DNA. Radiation can induce DNA damage 
either directly, hitting DNA molecules, or indirectly via ionization of water molecules, which 
induce the formation of highly reactive water radicals. These free radicals in turn hit other 
molecules, e.g. DNA, lipids and proteins [152]. High LET radiation causes DNA damage 
mostly directly, whereas low LET radiation induces most of the damages via indirect way.  
Besides damaging DNA and other cellular components, ionizing radiation has a variety of 
other effects, which affect cells and tissues. These effects are cell type and dose dependent, 
and include, inter alia, cell death, inducing of reactive oxygen species (ROS), changes in 
protein and gene expression as well as morphological and functional changes [153]–[155].  
The main goal of tumor radiotherapy is the induction of tumor cell death and the activation of 
immune system. In contrast, the aim of low-dose radiation treatment is to modulate the 
immune response to attenuate a pre-existing inflammatory state. The beneficial ability of low-
dose radiation to switch the phenotype of inflammatory cells to an anti-inflammatory without 
affecting their functionality is used, inter alia, for the therapy of degenerative joint diseases 
[138], [156]. 
1.9 Aims 
Based on the current knowledge, in the present work, it was hypothesized that low-dose 
irradiation inhibits adipokine-induced inflammation in the joints of MSD patients. To obtain 
the best possible understanding of radiation effects on adipokine-induced inflammation, the 
investigations were performed in vivo and in vitro. To verify the hypothesis, following 
questions were addressed in this work: 
- In vivo: Does radon treatment have an influence on the circulating levels of 
adipokines in MSD patients? The investigations were performed within the scope of 
RAD-ON01 study (see chapter 2.1);  
 
- In vitro: 
a) Do the adipokines adiponectin and visfatin have an influence on synovial 
fibroblasts? Thereby the synovial fibroblasts obtained from patients with rheumatoid 
arthritis and from healthy donors were used; 
b) If there is an effect on synovial fibroblasts, does irradiation of adipokine-stimulated 
synovial fibroblasts alters this effect? For this, the adipokine-stimulated synovial 
fibroblasts were irradiated with different doses of X-rays; 
 
- In vitro: Since adipokines are mostly produced by adipose tissue, is the differentiation 
or activity of adipocytes influenced by radiation? For this purpose, the response of 
(pre)adipocytes to X-ray irradiation was investigated.  
The data obtained within scope of this thesis should provide new insights on the molecular 
and cellular mechanisms related to low-dose radio- and radon therapy. 
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2 Methods 
2.1 Patient study RAD-ON01 
Study design 
For this study, 100 patients were enrolled, who suffered from chronic degenerative 
musculoskeletal diseases (MSD) of spine and/or joints. The unblinding took place at the end 
of last follow-up (6 months after treatment start). The study was carried out in accordance 
with the recommendations of the ethical review committee of the Bavarian State Chamber of 
Physicians (Bayerische Landesärztekammer, Munich, Germany, ethical approval BLAK 
#12131). All patients have granted their written informed consent. Full study description is 
published by Ruehle et al [140]. 
Patients and radon treatment 
In March 2013, 100 patients were separated in two groups of 50 patients each. The first group 
was treated with 100% radon water, the second group – with an even proportion of CO2 and 
radon water. The radon treatment, consisted of a series of 9 baths with duration of 20 min 
each over 3 weeks, was performed in the certified health resort Bad Steben, Germany. The 
temperature (34°C) and the humidity (60%) were controlled. The average activity of the 
radon containing baths was 1200 Bq/l. In the present work, in total 44 patients were 
analyzed.  
The following inclusion criteria for patients were applied: 
1. Age 18-75 years 
2. Chronic degenerative MSD 
3. Pain duration more than 1 year 
4. Pain intensity VAS>4 
5. Effective contraception 
6. Accessibility for treatment and follow-up 
7. Willingness to cooperate 
8. Written consent 
9. No participation in other studies (3 months before and during the participation in  
RAD - ON01 study)  
The following exclusion criteria for patients were applied: 
1. Pregnant or nursing women 
2. Childbearing or procreative people, which are incapable to consequent contraception 
during the treatment 
3. Heart failure >NYHA II or EF >40% 
4. Not adjustable hypertonia >180/90 mmHg 
5. Manifest, medicinal not adjustable hyperthyroidism 
6. Acute inflammatory or consuming diseases 
7. Lack of compliance with the protocol 
8. Continuing misuse of drugs, alcohol or medicaments 
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9. Missing willingness to storage and handling of personal disease data in frame of study 
10. Participation in other study at the same time 
Clinical and diagnostic investigations 
The patients were questioned and medically examined by a doctor before and then 6, 12, 18 
and 30 weeks after treatment start. Pain duration was determined by evaluation of pain 
diaries filled out by patients. Peripheral blood was drawn at indicated time points, transported 
to the laboratory and possessed within 24 h. The serum samples were frozen at -80° C. In 
framework of this study, adipokines and marker of bone remodeling were measured in the 
blood serum using ELISA assays. 
2.2 Cell culture  
General conditions 
Incubator conditions for all cell types were set to a relative humidity of 95%, 5% CO2 and 
37°C. Unless indicated otherwise, the medium change was performed two or three times a 
week. Detailed descriptions of the media composition see in the appendix (Tab. A.5). For cell 
count the automated cell counter TC20™ was used. 
Primary human pre-adipocytes 
Primary human pre-adipocytes were purchased from Lonza Ltd. These were isolated from 
subcutaneous fat of healthy donors. The cells were cultured in preadipocyte growth medium 
(Lonza Ltd.) until reaching the confluence. For the differentiation into adipocytes, appropriate 
supplements (Lonza Ltd.) including insulin, dexamethasone, 3-Isobutyl-1-methylxanthin 
(IBMX) and indomethacin were used. Medium was changed every second day. The first fat 
droplets were visible on day three after initiation of differentiation.  
SGBS cells 
Simpson-Golabi-Behmel syndrome (SGBS) pre-adipocytes were kindly provided by Prof. Dr. 
Wabitsch and Prof. Dr. Fischer-Posovszky, University Hospital Ulm. The SGBS cells were 
derived from subcutaneous fat of a patient with SGBS. Simpson-Golabi-Behmel syndrome is a 
rare congenital disorder, which is characterized by a pre- and postnatal overgrowth of several 
organs. Because of a high capacity for adipogenic differentiation, SGBS cells are an excellent 
tool for studies of adipocytes in vitro [68]. The protocol for cultivation and differentiation of 
cells, provided by Prof. Dr. Wabitsch, was strictly followed. Briefly summarized, the cells were 
grown in the DMEM/F12 medium, containing 10% FCS until reaching the confluence. To 
promote adipogenic differentiation, serum-free DMEM/F12 medium containing rosiglitazone, 
dexamethasone (DEX), IBMX, cortisol, transferrin, triiodotyronin (T3) and human insulin was 
added (day 0). After four days medium was replaced by medium containing cortisol, 
transferrin, triiodotyronin and human insulin (Fig. 2.1). The first fat droplets were visible on 
day three after initiation of differentiation. In order to perform experiments with 
undifferentiated pre-adipocytes, the growth medium containing 10% FCS without 
differentiation factors was used for cell cultivation. 
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Fig. 2.1 Differentiation protocol for SGBS cells. Modified according to [68] 
For the expansion of pre-adipocytes, different sizes of cell culture flasks and dishes were used. 
To achieve a high differentiation rate, primary human pre-adipocytes and SGBS pre-
adipocytes were cultivated in Petri dishes (Ø 35 and 60 mm) or on chamber slides. For 
irradiation experiments, the pre-adipocytes were irradiated at confluence and differentiation 
medium was added immediately after irradiation (day 0). 
Primary human synovial fibroblasts  
Primary human normal synovial fibroblasts (NSF, obtained from knee joints of healthy 
donors) and rheumatoid arthritis synovial fibroblasts (RASF, obtained from knee joints of 
patients with rheumatoid arthritis) were purchased from Cell Applications. Furthermore, 
primary human synovial fibroblasts from two patients with rheumatoid arthritis were kindly 
provided by Prof. B. Suess and Dr. M. Saul, Technical University Darmstadt. Both cell types 
were cultivated identically in DMEM containing 10% FCS to reaching the confluence. 
Cultured synovial fibroblasts were used for experiments between passages 1-3, because in the 
higher passages the cell proliferation was decelerated. 
2.3 Stimulation experiments  
Dose- and time-dependent response of SF to visfatin stimulation 
To evaluate the optimal concentration and duration for stimulation, the dose- and time-
dependent effects of visfatin were investigated in a first step. Due to a shortage of NSF, 
experiments on dose and time-dependence were done only in RASF.  
The cells were grown in CD35 dishes until reaching confluence. After rinsing the dishes with 
PBS, the cells were treated with different concentrations of human recombinant visfatin (100, 
250, 500 and 1000 ng/ml, BioVendor) in serum-free DMEM. Unstimulated cells incubated in 
serum-free DMEM were served as control. Cell supernatants were collected and the cell 
number was determined at different time points (12, 24, 36 and 48 h). Dose- and time-
dependent induction of cytokines IL-6 and IL-8 was detected using ELISA (eBioscience). 
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Adipokine stimulation of synovial fibroblasts for irradiation experiments 
To examine the effect of X-ray irradiation on adipokine-induced release of inflammatory 
cytokines by human synovial fibroblasts, NSF and RASF were rinsed with PBS and then 
treated with human recombinant adiponectin (5 µg/ml, RayBiotech) or human recombinant 
visfatin (250 ng/ml, BioVendor). The treatment was performed in serum-free DMEM to avoid 
serum-dependent effects. The cells were irradiated with different doses of X-rays (0.5, 2 and 
10 Gy) 24 h after the stimulation. Collection of the cell supernatants, isolation of RNA and the 
cell count were performed 24 h after irradiation (Fig. 2.2). Non-stimulated and non-irradiated 
NSF and RASF were used as controls. The medium was not changed during the experiment.
  
 
Fig. 2.2 Experimental setup for stimulation and irradiation of NSF and RASF 
2.4 Irradiation experiments 
All in vitro experiments were carried out with X-ray irradiation. Irradiation was performed on 
an X-ray tube (IV320-13, Seifert, Ahrensburg) with a tube voltage of 250 kV and a cathode 
current of 16 mA (Fig. 2.3). The cells were exposed at room temperature with an approximate 
dose rate of 1 Gy/min. The PTW-SN4 detector was used for dosimetry. The duration of total 
irradiation procedure including exposure and transport between incubator and the irradiation 
room was approximately 30 min. Non-irradiated cells (controls) were subjected to the same 
conditions as the irradiated samples (transport to the X-ray tube, room temperature during 
irradiation procedure etc.) 
 
Fig. 2.3 X-ray irradiation of the samples. For the irradiation experiments samples and the sensor of dosimeter were 
placed below the exit window of X-ray tube 
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Clonogenic cell survival assay 
The clonogenic survival assay is a common method to determine the reproductive ability 
(colony formation) of a single cell in vitro. Hence the cell survival curve shows the 
relationship between different doses of irradiation and the fraction of cells, which still retain 
their reproductive ability after treatment. To assess clonogenic survival, the cells were 
cultivated in T75 flasks, irradiated at subconfluence, trypsinized and seeded after appropriate 
dilutions (Tab. 2.1). After 14 days of cultivation, the cells were stained with methylene blue 
for 30 min and washed with distilled water. Colonies (> 50 cells) were counted using the 
light microscope. The experiments were done twice with three replicates for each dose and 
cell type. 
Irradiation dose, Gy RASF/75 cm2 NSF/75 cm2 
0 100 
300 
500 
100 
500 
1000 
0.5 200 
500 
750 
250 
500 
1000 
1 500 
750 
1000 
500 
1000 
1500 
2 750 
1000 
1500 
1000 
1500 
2000 
5 1000 
1500 
2000 
1500 
2000 
5000 
10 1500 
2000 
5000 
2000 
5000 
Tab. 2.1 Seeding of synovial fibroblasts for clonogenic cell survival assay 
2.5 Detection and analysis of adipocyte differentiation 
Oil Red O staining of intracellular triglycerides 
To determine triglyceride accumulation in adipocytes during differentiation, Oil Red O 
staining was used. Prior to staining, the cells were washed with PBS and fixed with 10% 
formalin for 30-60 min at room temperature. After removing the formalin and washing the 
cells with distilled water, 60% isopropanol was added for 2-5 min. Then the cells were stained 
with Oil Red O working solution (appendix, Tab. A.2) for 5 min at room temperature with 
slowly rotation. Finally, the cells were carefully washed with distilled water and the redly 
appearing lipids were directly visualized and imaged using a phase contrast microscope (Fig. 
2.4). 
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DAPI staining 
For visualization of the nuclei of adipocytes, DAPI staining was performed. For this, the cells 
were washed with distilled water after performing Oil Red O staining, and then DAPI working 
solution (1µg/ml) was added for 5 min. Afterwards, the cells were washed twice with PBS, 
few drops of Vectashield™ were added and the slides were covered with a glass cover slip. 
Blue appearing nuclei were detected at a wavelength of 340 nm. 
 
Fig. 2.4 Oil Red O and DAPI stained adipocytes. (1) Pre-adipocytes, (2) Mature adipocytes were stained with Oil 
Red O and (3) Mature adipocytes were stained with Oil red O and DAPI on day 20 after initiation of differentiation 
Quantification of triglyceride accumulation 
Lipid accumulation was quantified by the measurement of extracted Oil Red O. After staining 
with Oil Red O, the cells were carefully washed with distilled water and 4% triton X-100 
(Sigma-Aldrich) in isopropanol was added to permeabilize the cells. The dishes were 
incubated 15 min at room temperature by gently shaking. Following Oil Red O extraction 100 
µl per sample was transferred into a 96-well plate and the absorbance was measured at 540 
nm using photometer ELx808 (Biotec).  
Determination of adipocyte differentiation rate 
To get an overview about the differentiation rate during the differentiation process, cells 
cultured on chamber slides were stained with Oil Red O and DAPI on defined days and 7 
randomly selected areas per slide were analyzed. For this, all DAPI-stained cells and all Oil 
Red O- positive cells were counted and the differentiation rate was calculated as follows:  
𝐷𝑅 =
𝑛 (𝑂𝑖𝑙 𝑅𝑒𝑑 𝑂)
𝑛 (𝐷𝐴𝑃𝐼)
∗ 100% 
2.6 Enzyme-linked immunosorbent assay (ELISA) 
To determine the released cytokine concentration of adipocytes and synovial fibroblasts in the 
cell supernatants, and the concentration of adipokines in the serum of patients, ELISA assays 
were performed. ELISA is an analytical biochemical assay, which is based on the specific 
interaction between antibody and corresponding antigen. The antibody binds antigen from 
the sample, which can then be photometrically detected by a color change of enzyme-coupled 
secondary antibody. The concentration of the dye is thereby proportional to the antigen 
concentration. Depending on the sensitivity of the ELISA (appendix, Tab. A.1) and cytokine 
concentration, the samples were used either undiluted or diluted according to the protocol. 
Manufacturer instructions were thereby strictly followed. 
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2.7 Quantitative real-time polymerase chain reaction (qPCR) 
RNA isolation 
RNA isolation was performed using RNeasy Mini Kit (Qiagen) according to the manufacturer 
instructions. The cells (1x106 - 1x107) were trypsinized and centrifuged 8 min at 300 x g. The 
cell pellet was diluted in 350 µl buffer RLT and 350 µl 70% ethanol was added. Cell 
suspension was mixed and transferred directly into the RNeasy spin column and centrifuged 
15 sec at 8000 x g. In the next step, the RNeasy spin column was washed with 700 µl of buffer 
RW1 15 sec at 8000 x g, followed by two washing steps with 500 µl of buffer RPE. In the last 
step, the RNeasy spin column was placed in a 1.5 ml collection tube, 50 µl RNase-free water 
was added and RNA was eluted by centrifugation 1 min at 8000 x g. The RNA concentration 
and purity were analyzed using Colibri Microvolume Spectrometer (Titertek Berthold). 
Because nucleic acids absorb light at 260 nm, and proteins and other contaminants – at 280 
nm, the ratio 260/280 typically indicates purity of RNA or DNA. A 260/280 ratio of 
approximately 2.0 indicates a high purity of RNA, a ratio of approximately 1.8 is generally 
accepted as high purity for DNA. 
cDNA synthesis by reverse transcription 
The isolated RNA was converted to the complementary DNA (cDNA) using RevertAid™ First 
Strand cDNA Synthesis Kit (ThermoFisher Scientific) according to manufacturer instructions. 
For the cDNA synthesis, 1 µg of template RNA was used. Following reagents (Tab. 2.2) were 
added in a nuclease-free tube, mixed and incubated 60 min at 42ºC. The reaction was stopped 
by heating at 70ºC for 5 min. cDNA samples were stored at -80ºC. 
total RNA 1 µg 
Oligo (dT)18 primer 1 µl 
Water, nuclease-free to 12 µl 
5x Reaction Buffer 4 µl 
RiboLock RNase Inhibitor (20 U/µl) 1 µl 
10 mM dNTP Mix 2 µl 
RevertAid M-MuLV RT (200 U/µl) 1 µl 
Total volume 20 µl 
Tab. 2.2 First strand cDNA synthesis mix 
Quantitative real-time PCR (qPCR) 
Real-time qPCR is a very sensitive method to increase extent of a target DNA sequence, which 
is directly related to the amount of fluorescence emitted from a reporter molecule. In this 
project, the SYBR® Green detection method was used. SYBR® Green dye binds to double-
stranded DNA and the level of fluorescence increases only if it is bound to DNA. Measuring of 
fluorescence and thus quantification of the product is performed after each PCR cycle. Ct 
value shows thereby the cycle number, at which the fluorescence signal is over the baseline 
signal (threshold, Fig. 2.5A). Because SYBR® Green dye binds non-specifically any double 
strand DNA, including e.g. primer dimers, a melting curve analysis was performed to ensure 
that the target product was amplified. For this analysis, the temperature of reaction was 
increased to 95ºC, whereas double-stranded DNA “melts” into single-stranded DNA, while 
incorporated dye dissociate from the DNA and the fluorescence level decreases. Changes in 
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fluorescence then are plotted against temperature for visualization of the melting dynamics 
(Fig. 2.5B).  
 
Fig. 2.5 A typical amplification plot and a melt curve of the SYBR® Green based qPCR. (A) Amplification of the 
target genes during one qPCR run. The normalized reporter value (∆Rn) is plotted against number of cycles (Ct 
value). (B) The melting curve of GAPDH. Change in fluorescence/ change in temperature (-R) is plotted against 
temperature 
The qPCR reactions were performed using StepOnePlus real-time PCR System (Applied 
Biosystems), thereby comparative Ct (∆∆Ct) method with melting curve analysis was applied. 
It is a standard method to analyze relative changes in the gene expression. For performing 
∆∆Ct method, a suitable endogenous control and a reference sample are required. 
Comparison of the Ct value of a target gene with that of the endogenous control, which is 
constantly expressed in all samples, allows normalization of the gene expression level to the 
general amount of the cDNA. The expression in the samples is then compared to the 
expression in the reference sample. In this project, the housekeeping gene GAPDH was served 
as an endogenous control and the non-irradiated samples – as a reference. “QuantiTect SYBR® 
Green PCR Kit” and “QuntiTect Primer Assay” were purchased from Qiagen. The components 
of one PCR reaction and the cycling conditions are listed in Tab. 2.3 and Tab. 2.4. 
Water, nuclease-free 18 µl 
SYBR
®
 Green MasterMix 25 µl 
Primer (QuantiTect Primer Assay) 5 µl 
cDNA 2 µl (100 ng) 
Total volume 50 µl 
Tab. 2.3 PCR reaction mix 
 
Step Time Temperature Comments 
PCR initial activation 
step 
15 min 95ºC Activation of HotStarTaq DNA 
polymerase 
3-step cycling:    
Denaturation 15 sec 94ºC  
Annealing 30 sec 55ºC  
Extension 30 sec 72ºC Fluorescence data collection 
Number of cycles 40   
Tab. 2.4 PCR cycling conditions 
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2.8 Statistical analysis 
Statistical analysis was performed using two-tailed t-test after checking for normal 
distribution with D’Agostino and Pearson test. For the not normally distributed data, the 
Wilcoxon matched pairs signed rank test was used (GraphPad Prism 6). The results were 
estimated as significant for p < 0.05. For evaluating of relationships, Pearson’s and 
Spearman’s correlations were used for normal and non-normal distributions. 
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3 Results 
Adipokines are cytokines, specifically produced by adipose tissue [157]. In this thesis, the 
impact of a radon treatment on adipokine serum levels in patients with MSD was investigated. 
Adipokines have been shown to contribute to the inflammation and joint destruction in RA 
and OA by induction of IL-6, IL-8 and MMP-1 in synovial fibroblasts. Thus, they are 
considered as potential targets for the therapy of rheumatoid arthritis and other MSD [158], 
[159]. Since in this thesis it was hypothesized that low-dose radiation affects the adipokine-
induced inflammation in arthritic joints, the response of human synovial fibroblasts to 
adipokine stimulation and its modulation by radiation exposure were investigated (in vitro). 
To clarify whether ionizing radiation can affect the release of adipokines by cells of adipose 
tissue, the radiation response of adipocytes was investigated (in vitro).  
3.1 Investigations of serum levels of adipokines in radon-treated patients 
(Patient study RAD-ON01) 
The main goal of this prospective study (RAD-ON01) was to investigate a putative anti-
inflammatory effect of radon exposure and the impact on the immune- and skeletal system of 
patients suffering from musculoskeletal diseases. To examine possible changes in the release 
of adipokines after radon spa treatment, the serum levels of visfatin, adiponectin, leptin and 
resistin have been measured in the serum of MSD patients. Furthermore, the relationship 
between adipokine levels and age, gender and pain duration (indicated by patients) was 
analyzed. The patient characteristics are summarized in Rühle et al [140].  
Visfatin serum levels 
Visfatin is an adipokine, which is closely related to synovial inflammation in the patients with 
MSD. Increased circulating visfatin levels have been found in patients with RA and OA  [94], 
[160]. Since it is known that elevated visfatin levels positively correlate with disease activity, 
this adipokine is considered to be a therapeutic target for the rheumatoid arthritis and other 
MSD [99], [161]. 
As shown in Figure 3.1A, the results demonstrated a significant decrease of visfatin serum 
levels, which occurs 12 weeks after therapy start and still persist at the end of follow-up 
period (30 weeks). The mean level of visfatin before treatment (0 weeks) was 2.31 ng/ml 
(0.433 – 8.39 ng/ml, n=44) and at 30 weeks after treatment start – it was 1.26 ng/ml (0.265 
– 4.65 ng/ml, n=44). Serum concentrations of visfatin were significantly higher in males than 
in females (Fig. 3.1B). No significant correlations between the visfatin levels and the age of 
the patients were found (Fig. 3.1C). Visfatin levels were significantly lower in the serum of 
patients, which have reported less pain at indicated time points (Fig. 3.1D). 
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Fig. 3.1 Effect of radon treatment on the serum visfatin levels and the relationship between visfatin levels and 
gender, age and pain duration in patients with MSD. (A) The concentration of visfatin in serum was measured at 
the indicated weeks before (0 weeks) and after onset of the therapy (6-30 weeks). Boxplots show the median, 
Tukey whiskers (median ± 1.5 times interquartile range), mean (+) and outliers (•). (B) Comparison of visfatin 
serum concentrations between male and female patients. (C) Correlation of serum visfatin concentrations to the 
age of patients. (D) Association between serum visfatin levels and pain duration. N=44, (A) **p ≤ 0.01, ****p ≤ 
0.0001, Wilcoxon matched-paired signed rank test. (B), (D) *p ≤ 0.05, Mann Whitney test 
Adiponectin serum levels 
Adiponectin is one of the most widely studied adipokines. Levels of adiponectin are higher in 
serum and synovial fluid of patients with RA in comparison to healthy donors. Moreover, they 
have been found to correlate with disease activity and rheumatoid factor RF [158], [162]. 
Adiponectin is suggested to support the inflammatory and joint destructive processes in RA. 
The analysis of adiponectin showed no significant changes over 30 weeks (Fig. 3.2A). The 
mean level of adiponectin was 9.85 µg/ml (9.65 µg/ml at 0 weeks, 10.49 µg/ml at 30 weeks). 
Serum concentrations of adiponectin were significantly higher in females than in males (Fig. 
3.2B). No significant correlations between adiponectin levels and age (Fig. 3.2C) or pain 
duration (Fig. 3.2D) were found. 
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Fig. 3.2 Effect of radon treatment on the serum adiponectin levels and the relationship between adiponectin 
levels and gender, age and pain duration in patients with MSD. (A) The concentration of adiponectin in serum 
was measured at the indicated weeks before (0 weeks) and after onset of the therapy (6-30 weeks). Boxplots show 
the median, Tukey whiskers (median ± 1.5 times interquartile range), mean (+) and outliers (•). (B) Comparison of 
adiponectin serum concentrations between male and female patients. (C) Correlation of serum adiponectin 
concentrations to the age of patients. (D) Association between serum adiponectin levels and pain duration.  N=39, 
**p ≤ 0.01 Mann Whitney test 
Leptin and resistin serum levels 
The adipokines leptin and resistin are generally considered as pro-inflammatory cytokines and 
play a potential role in MSD, in particular in RA. Serum levels of both adipokines were shown 
to be elevated in serum of RA patients [86], [94], [158]. However, their role in RA remains 
unclear. 
The serum levels of leptin and resistin were not significantly changed after radon treatment 
(Fig. 3.3A, 3.4A). The mean level of leptin was 24.2 ng/ml over the follow-up period (22.28 
ng/ml at 0 weeks, 23.08 ng/ml at 30 weeks), of resistin – 4.45 ng/ml (4.2 ng/ml at 0 weeks, 
4.33 at 30 weeks). Serum concentrations of leptin were significantly higher in females than in 
males (Fig. 3.3B). In contrast, no gender-specific differences were found for resistin serum 
levels (Fig. 3.4B). No correlations were found between serum levels and age or pain duration 
neither for leptin, nor for resistin (Fig. 3.3C, D, 3.4C, D).  
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Fig. 3.3 Effect of radon treatment on the serum leptin levels and the relationship between leptin levels and 
gender, age and pain duration in patients with MSD. (A) The concentration of leptin in serum was measured at 
the indicated weeks before (0 weeks) and after onset of the therapy (6-30 weeks). Boxplots show the median, 
Tukey whiskers (median ± 1.5 times interquartile range), mean (+) and outliers (•). (B) Comparison of leptin serum 
concentrations between male and female patients. (C) Correlation of serum leptin concentrations to the age of 
patients. (D) Association between serum leptin levels and pain duration. N=32, ****p ≤ 0.0001 Mann Whitney test 
3.2 Radiation-induced changes in human synovial fibroblasts  
Rheumatoid arthritis synovial fibroblasts (RASF) play an essential role in the pathogenesis of 
rheumatoid arthritis. They contribute to inflammation and joint destruction by inducing the 
expression of pro-inflammatory and matrix-degrading factors in different cell types of synovia. 
Little is known about effects of ionizing radiation on human synovial fibroblasts. One of the 
aims of this thesis was to compare NSF and RASF in their response to radiation and to 
adipokine stimulation. 
3.2.1 Proliferation of human synovial fibroblasts after irradiation 
The effect of X-ray radiation on the proliferation of human synovial fibroblasts was 
investigated over a period of 28 days. Thereby NSF and RASF were compared. In the 
experiments presented here, the cell numbers of irradiated synovial fibroblasts, both NSF and 
RASF, were dose-dependent decreased compared to the control (Fig. 3.5). However, the 
changes were more pronounced for NSF compared to RASF. While the proliferation of 2 Gy-
irradiated NSF has slowed down considerably from day 10 on, and proliferation of 10 Gy-
irradiated NSF was completely inhibited over the all period of observation, the RASF showed 
only the slight trend towards reduced proliferation after irradiation.  
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Fig. 3.4 Effect of radon treatment on the serum resistin levels and the relationship between leptin levels and 
gender, age and pain duration in patients with MSD. (A) The concentration of resistin in serum was measured at 
the indicated weeks before (0 weeks) and after onset of the therapy (6-30 weeks). Boxplots show the median, 
Tukey whiskers (median ± 1.5 times interquartile range), mean (+) and outliers (•). (B) Comparison of resistin 
serum concentrations between male and female patients. (C) Correlation of serum resistin concentrations to the 
age of patients. (D) Association between serum resistin levels and pain duration. N=33 
 
 
Fig. 3.5 Proliferation of human synovial fibroblasts after X-ray irradiation. (A) Synovial fibroblasts from healthy 
donors (NSF) and (B) from patients with rheumatoid arthritis (RASF) were irradiated with 0.5, 2 and 10 Gy X-rays 
and cultivated over 28 days. Cell counting was performed at regular intervals. Mean, SEM. N=3 for NSF, N=4 for 
RASF 
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3.2.2 Clonogenic survival of human synovial fibroblasts after irradiation 
In addition to proliferation, clonogenic survival was determined to evaluate whether radiation 
affects an aggressive proliferative capacity of RASF, contributing to attenuation of 
inflammation in the joint. 
As a first step, the plating efficiency of human synovial fibroblasts was measured. Although 
the cells were seeded at different cell densities (see chapter 2.4) and different types of culture 
flasks (T25 and T75) were used, the plating efficiency was found to be around 7% for NSF as 
well as for RASF. In the next step, the clonogenic cell survival assay was performed. The 
analysis of this assay showed that neither NSF nor RASF were able to form the colonies after 
irradiation (a colony is defined to consist of at least 50 daugter cells). Typical colonies were 
only found in the unirradiated samples (NSF) (Fig. 3.6-1). For the cells (NSF) irradiated with 
0.5 Gy, few small (<50 cells) cell “crowds” were observed (Fig. 3.6-2). In samples irradiated 
with 1, 2, 5 or 10 Gy only single cells were present (Fig. 3.6-3).  
 
Fig. 3.6 Morphology of NSF as observed in the clonogenic cell survival assay. The cells were cultivated 14 days 
after irradiation with X-rays and stained with methylene blue. (1) Typical colony of NSF (control), (2) Cell “crowd” 
after exposure to 0.5 Gy X-rays and (3) Cells after irradiation with 5 Gy of X-rays 
3.3 Radiation-induced changes in the response of human synovial 
fibroblasts to the adipokine stimulation 
Adipokines such as adiponectin and visfatin are known to exert a pro-inflammatory influence 
on RASF. In order to investigate the effects of adipokines on NSF, and to compare them with 
the effects on RASF, both cell types (NSF and RASF) were treated with the corresponding 
recombinant adipokine for 48 h. The release and gene expression of the inflammatory 
cytokines (IL-6, IL-8, MCP-1) as well as matrix-degrading enzymes (MMP-1, MMP-3) were 
analyzed. In addition, release and gene expression of adiponectin, adiponectin receptor 
(AdipoR) and visfatin were examined. 
To evaluate whether irradiation of human synovial fibroblast affects the adipokine-induced 
release of above-mentioned pro-inflammatory cytokines and matrix-degrading enzymes, NSF 
and RASF were treated with the corresponding adipokine 24 h prior to X-ray irradiation. Cell 
supernatants were collected 24 h after irradiation and release of IL-6, IL-8, MCP-1 and MMP-1 
was analyzed. In addition, gene expression analysis of mentioned factors was performed to 
verify results obtained from ELISA assays (appendix, Fig. A.1, A.2).  
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3.3.1 Effect of adiponectin on human synovial fibroblasts 
To evaluate the effects of adiponectin on human synovial fibroblasts, NSF and RASF were 
treated with 5 µg/ml adiponectin in serum-free medium for 48 h. Levels of IL-6, IL-8, MCP-1 
as well as MMP-1 and MMP-3 were determined in cell supernatants and compared between 
NSF and RASF. Results obtained for the release were approved by gene expression analysis. 
The concentration of 5 µg/ml was chosen according to the literature. An additional 
experiment on time-dependent effects of adiponectin showed that the strongest induction of 
IL-6 is reached 48 h after treatment (appendix, Tab. A.8). Therefore, these parameters (5 
µg/ml; 48 h) were chosen for subsequent experiments.  
Adiponectin-induced changes in release and expression of pro-inflammatory factors by 
human synovial fibroblasts 
As shown in Fig. 3.7, adiponectin increased the release of IL-6, IL-8 and MCP-1 in both cell 
types (NSF and RASF); however, the effect was stronger in RASF. For example, after 
treatment with 5 µg/ml adiponectin the IL-6 level in NSF was two- and in RASF - almost nine-
fold increased (Fig. 3.7A). Similarly, IL-8 concentration was eight-fold higher in NSF and 
nineteen-fold higher in RASF after treatment with the same concentration of adiponectin (Fig. 
3.7B). MCP-1 levels were two-fold (NSF) and three-fold (RASF) higher compared to the basal 
concentrations (Fig. 3.7C). Noteworthy, the basal levels of stated cytokines do not differ 
significantly between NSF (Mean ± SEM, pg/104 cells: 1.38 ± 0.5 (IL-6); 1.4 ± 0.09 (IL-8); 
38.8 ± 6.5 (MCP-1)) and RASF (Mean ± SEM, pg/104 cells: 2.09 ± 1.09 (IL-6); 3.18 ± 2.1 
(IL-8); 23.6 ± 8.4 (MCP-1)). Although clear differences in the release of IL-6 and IL-8 were 
observed in all samples after stimulation with adiponectin, the statistical significance could 
not be reached. Details on the changes in the cytokine release by NSF and RASF are listed in 
Tab. 3.1.  
In contrast, the fold change of MMP-1 level was greater in NSF (nine-fold) than in RASF (six-
fold, Fig. 3.8A) after stimulation with adiponectin. No marked differences were observed for 
MMP-3 concentrations in both cell types. With respect to the basal levels of matrix-degrading 
enzymes, RASF exhibited higher concentration of MMP-3 than NSF (Mean ± SEM, pg/104 
cells: 60.7 ± 3.03 (NSF); 122.03 ± 16.9 (RASF)) and mostly the same level of MMP-1 (Mean 
± SEM, pg/104 cells: 15.1 ± 9.8 (NSF); 26.7 ± 12.9 (RASF)). 
 
 34 
Fig. 3.7 Effect of adiponectin on cytokine release by human synovial fibroblasts. Synovial fibroblasts from healthy 
donors (NSF) and from patients with rheumatoid arthritis (RASF) were treated or not with 5 µg/ml adiponectin for 
48 h. Amounts of (A) IL-6, (B) IL-8 and (C) MCP-1 in cell supernatants were measured using ELISA assay. Boxplots 
show the median, Tukey whiskers (median ± 1.5 times interquartile range) and mean (+). N=4 
Fig. 3.8 Effect of adiponectin on MMP-1 and MMP-3 release by human synovial fibroblasts. Synovial fibroblasts 
from healthy donors (NSF) and from patients with rheumatoid arthritis (RASF) were treated or not with 5 µg/ml 
adiponectin for 48 h. Amounts of (A) MMP-1 and (B) MMP-3 in cell supernatants were measured using ELISA assay. 
Boxplots show the median, Tukey whiskers (median ± 1.5 times interquartile range) and mean (+). N=4 for MMP-1, 
N=3 for MMP-3 
In addition to the analysis of the cytokine release in NSF and RASF, the gene expression 
profiles of both cell types were examined (Fig. 3.9). Considering the strong induction of 
cytokines IL-6, IL-8 and matrix-degrading enzyme MMP-1, the focus was set on the gene 
expression of these factors and the analysis was performed using quantitative real-time PCR. 
The results confirm the strong upregulation of genes, coding for IL-6, IL-8 and MMP-1. No 
significant differences were found for MCP-1 and MMP-3. The expression of adiponectin 
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receptor 1 (AdipoR) and visfatin remained as well unchanged. It is notable that the fold-
changes of all analyzed genes were almost the same for NSF and RASF (Tab. 3.1). 
 
Fig. 3.9 Regulation of gene expression in human synovial fibroblasts by adiponectin. Expression of stated genes 
in (A) NSF and (B) RASF was analyzed using qPCR. The data are normalized to GAPDH gene expression and to the 
gene expression of untreated control. Bars indicate fold change induction after 48 h treatment with 5 µg/ml 
adiponectin. Mean, SEM. N=4, *p ≤ 0.05, ***p ≤ 0.001, two-tailed t-test 
                           NSF                             RASF 
Name Fold change Fold change Fold change Fold change 
  ELISA qPCR ELISA qPCR 
IL-6 2.29±0.6 7.4±3.85 9.14±4.5 8.25±4.49 
IL-8 (CXCL8) 8.02±3.36 15.6±4.02 19.05±15.1 12.7±1.25 
MCP-1 2.04±0.35 1.23±0.27 3.67±1.98 1.31±0.32 
MMP-1 9.99±4.32 29.14±12.89 6.78±1.91 26.65±12.25 
MMP-3 1.8±0.42 1.93±0.93 1.52±0.36 5.0±3.28 
AdipoR  1.71±0.78   1.04±0.24 
Visfatin   2.3±0.67   2.98±0.66 
Tab. 3.1 Changes in cytokine and gene expression profiles of NSF and RASF after treatment with adiponectin. 
Mean ± SEM 
3.3.2 Effect of visfatin on human synovial fibroblasts 
Apart from investigations on adiponectin effects, the influence of another adipokine - visfatin - 
on human synovial fibroblasts was examined. For this, NSF and RASF were treated with 250 
ng/ml of visfatin in serum-free medium for 48 h. Levels of IL-6, IL-8, MCP-1 and MMP-1 were 
determined in cell supernatants and compared between NSF and RASF. Results obtained for 
the release were approved by gene expression analysis. To choose the optimal dose and 
treatment duration, first, the dose- and time dependency of visfatin effects were investigated. 
Due to a shortage of NSF, experiments on dose and time-dependence were done only in 
RASF. 
Dose- and time-dependent effects of visfatin on human synovial fibroblasts 
To assess the right parameter for further experiments, RASF were treated with different 
concentrations of visfatin (100; 250; 500 and 1000 ng/ml) in serum-free medium. Dose- and 
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time-dependent production of IL-6 and IL-8 was evaluated in the cell supernatants at different 
time points (12, 24, 36 and 48 h) after treatment (Fig. 3.10). The results showed that the 
concentration of 250 ng/ml visfatin causes a strong induction of both cytokines and the 
highest effect on the cytokine release was observed 48 h after treatment. For example, the 
basal concentration of IL-6 was increased from 0.56 pg/104 cells to 310.2 pg/104 cells at 12 h 
and 1345.5 pg/104 cells at 48 h (Fig. 3.10A). Therefore, these parameters (250 ng/ml; 48 h) 
were chosen for all of the following experiments.  
 
Fig. 3.10 Dose- and time-dependent effects of visfatin on synovial fibroblasts. Synovial fibroblasts from patients 
with rheumatoid arthritis (RASF) were treated or not with different concentrations of visfatin (100, 250, 500 and 
1000 ng/ml). Amounts of (A) IL-6 and (B) IL-8 in cell supernatants were measured using ELISA assay at different 
time points (12, 24, 36, 48 h). Mean, SD. N=2, n=4 
Visfatin-induced changes in release and expression of pro-inflammatory factors by 
human synovial fibroblasts 
As depicted in Fig. 3.11, visfatin has a very strong influence on synovial fibroblasts. For 
example, after treatment with 250 ng/ml visfatin, the IL-6 level in NSF was increased from 
1.48 ± 0.38 pg/104 cells to 89.09 ± 13.1 pg/104 cells and in RASF – from 1.05 ± 0.48 pg/104 
cells to 110.47 ± 94.6 pg/104 cells (Fig. 3.11A). Similarly, MMP-1 levels increased from 9.8 
± 3.02 pg/104 cells to 161.1 ± 40.5 pg/104 cells (NSF) and from 9.8 ± 0.11 pg/104 cells to 
151.0 ± 59.5 pg/104 cells (RASF) (Fig. 3.11D). Taken into account the wide variations 
between single experiments, the results suggest that the effect of visfatin with regard to 
induction of IL-6, IL-8, MCP-1 and MMP-1 is nearly the same on both NSF and RASF. Details 
on the changes in the cytokine release by NSF and RASF are listed in Tab. 3.2. 
As a next step, the gene expression analysis of factors listed above was performed (Fig. 3.12). 
The results confirmed a strong visfatin-induced induction of genes coding for IL-6 (90-fold 
higher for NSF and 60-fold higher – for RASF) and IL-8 (278- and 245-fold respectively). Also 
levels of MCP-1, MMP-1 and MMP-3 were appreciably higher compared to the basal 
concentrations. However, the gene expression of adiponectin and visfatin remained 
unchanged. Similar to adiponectin-induced changes, the changes in the expression of all 
analyzed genes caused by visfatin treatment were almost the same for NSF and RASF (Tab. 
3.2). 
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Fig. 3.11 Effect of visfatin on human synovial fibroblasts. Synovial fibroblasts from healthy donors (NSF) and from 
patients with rheumatoid arthritis (RASF) were treated or not with 250 ng/ml visfatin for 48 h. Amounts of (A) IL-6, 
(B) IL-8, (C) MCP-1 and (D) MMP-1 in cell supernatants were measured using ELISA assay. Mean, SEM. N=3, *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001, two-tailed t-test 
 
Fig. 3.12 Regulation of gene expression in human synovial fibroblasts by visfatin. Expression of stated genes in 
(A) NSF and (B) RASF was analyzed using qPCR. The data are normalized to GAPDH gene expression and to the 
gene expression of untreated control. Bars indicate fold change induction after 48 h treatment with 250 ng/ml 
visfatin. Mean, SEM. N=3, *p ≤ 0.05, **p ≤ 0.01, two-tailed t-test 
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                           NSF                             RASF 
Name Fold change Fold change Fold change Fold change 
  ELISA qPCR ELISA qPCR 
IL-6 72.8±25.8 92.8±29.8 252.5±239.2 63.2±13.3 
IL-8 (CXCL8) 142.8±37.6 278.2±55.2 324.39±179.79 245.7±63.0 
MCP-1 15.84±1.73 11.2±2.4 41.02±27.2 16.25±2.6 
MMP-1 16.8±1.29 24.9±2.8 43.96±21.6 14.47±8.8 
MMP-3  6.35±3.6  16.66±5.7 
Adiponectin  1.18±0.42   0.63±0.21 
Visfatin   3.02±0.19   2.41±0.34 
Tab. 3.2 Changes in cytokine and gene expression profiles of NSF and RASF after treatment with visfatin. Mean 
± SEM 
3.3.3 Radiation-induced changes in the response of human synovial fibroblasts to the 
adipokine treatment 
RASF are characterized by a highly pro-inflammatory phenotype. A variety of cytokines and 
matrix-degrading enzymes produced by activated RASF mediates inflammation process in the 
joint, contributes to the destruction of cartilage and bone, recruits more inflammatory cells 
and enhances the inflammatory state of RASF [37]. Adipokines such as adiponectin or visfatin 
are known to increase the production of several cytokines including IL-6 and IL-8 by synovial 
fibroblasts. For the treatment of rheumatoid arthritis, targeting of the pro-inflammatory 
properties of this cells is therefore of special interest.  
In this chapter, the impact of ionizing radiation on human synovial fibroblast with regard to 
production of pro-inflammatory cytokines IL-6, IL-8 and MCP-1 and matrix-degrading enzyme 
MMP-1 was investigated. The special focus was set on the radiation-induced changes in 
response of the cells to the treatment with adiponectin or visfatin.  
In the Fig. 3.13 and 3.14, the effects of X-rays radiation on the adiponectin-induced release of 
IL-6, IL-8, MMP-1 and MCP-1 by human synovial fibroblasts are shown. Furthermore, Fig. 
3.15 and 3.16 demonstrate the radiation-induced changes in the release of these factors in the 
visfatin-treated synovial fibroblasts. NSF and RASF were treated with the corresponding 
adipokine 24 h prior to irradiation with X-rays. Cell supernatants were collected 24 h after 
irradiation and amounts of above-mentioned factors were measured. Radiation effects on 1) 
cells pretreated with either adiponectin or visfatin and 2) untreated cells were determined 
and compared between NSF and RASF.  
First, the radiation effects on the untreated cells were evaluated. Notably, the human synovial 
fibroblasts turned out not to be affected by irradiation with regard to the cytokine release. No 
significant changes for both NSF and RASF were detected, even after the exposure to 10 Gy X-
rays. For example, the mean level of IL-6 for the unirradiated NSF was 1.38 ± 0.5 pg/104 
cells and for 10 Gy irradiated cells - 1.31 ± 0.13 pg/104 (Fig.3.13A). Similarly, for RASF the 
IL-6 levels were 2.09 ± 1.09 pg/104 cells (control) and 1.49 ± 0.45 pg/104 cells (10 Gy) 
(Fig.3.13B). The same situation was observed for IL-8, MCP-1 and MMP-1 levels (Fig. 3.13C-
D, 3.14A-D). 
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Fig. 3.13 Effect of X-ray irradiation on adiponectin-induced release of IL-6 and IL-8 by human synovial fibroblasts. 
Synovial fibroblasts from healthy donors (NSF) and from patients with rheumatoid arthritis (RASF) were treated or 
not with 5 µg/ml adiponectin for 24 h prior to irradiation with X-rays. Cell supernatants were collected 24 h after 
irradiation and amounts of (A-B) IL-6 and (C-D) IL-8 were measured using ELISA assay. Boxplots show the median, 
Tukey whiskers (median ± 1.5 times interquartile range) and mean (+). N=4 
In contrast, the radiation-induced changes in the release of pro-inflammatory factors were 
observed in the adipokine-treated cells. Moreover, the radiation response of NSF differed from 
that of RASF. Interestingly, the release pattern of all measured cytokines in RASF was 
relatively similar. While adipokine-treated NSF mostly showed either unchanged (Fig. 3.13A, 
C) or slightly increased (Fig. 3.15A, 3.16C) levels of cytokines, trends towards a decrease in 
IL-6, IL-8, MCP-1 (Fig. 3.13B, D, 3.14D, 3.15B, D, 3.16D) and MMP-1 (Fig. 3.14B, 3.16B) 
production were observed in all stimulation experiments with RASF. Additionally performed 
gene expression analysis confirmed most of the results obtained for the release (appendix, Fig. 
A.1, A.2). However, trends towards reduced expression of pro-inflammatory factors were only 
observed in the adiponectin-treated RASF.  
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Fig. 3.14 Effect of X-ray irradiation on adiponectin-induced release of MMP-1 and MCP-1 by human synovial 
fibroblasts. Synovial fibroblasts from healthy donors (NSF) and from patients with rheumatoid arthritis (RASF) were 
treated or not with 5 µg/ml adiponectin for 24 h prior to irradiation with X-rays. Cell supernatants were collected 
24 h after irradiation and amounts of (A-B) MMP-1 and (C-D) MCP-1 were measured using ELISA assay. Boxplots 
show the median, Tukey whiskers (median ± 1.5 times interquartile range) and mean (+). N=4 
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Fig. 3.15 Effect of X-ray irradiation on visfatin-induced release of IL-6 and IL-8 by human synovial fibroblasts. 
Synovial fibroblasts from healthy donors (NSF) and from patients with rheumatoid arthritis (RASF) were treated or 
not with 250 ng/ml visfatin for 24 h prior to irradiation with X-rays. Cell supernatants were collected 24 h after 
irradiation and amounts of (A-B) IL-6 and (C-D) IL-8 were measured using ELISA assay. Mean, SEM. N=3 
 
 
 42 
 
Fig. 3.16 Effect of X-ray irradiation on visfatin-induced release of MMP-1 and MCP-1 by human synovial 
fibroblasts. Synovial fibroblasts from healthy donors (NSF) and from patients with rheumatoid arthritis (RASF) were 
treated or not with 250 ng/ml visfatin for 24 h prior to irradiation with X-rays. Cell supernatants were collected 24 
h after irradiation and amounts of (A-B) MMP-1 and (C-D) MCP-1 were measured using ELISA assay. Mean, SEM. 
N=3 
3.4 Impact of ionizing radiation on differentiation of human adipocytes 
Adipose tissue is a complex endocrine organ that produces a variety of immune and 
inflammatory mediators [43], [88]. Adipocytes, the dominant cell type of adipose tissue, are 
known to support inflammatory processes and cartilage degradation in RA by release of 
different cytokines and adipokines. The adipokines induce IL-6, IL-8 and MMP-1 in synovial 
fibroblasts [11], [163], [164] and are considered to be a potential target for the therapy of 
rheumatoid arthritis. As there are no data available about radiation response of adipocytes, 
one of the aims of this work was to investigate whether ionizing radiation can affect 
differentiation process of adipocytes or the adipokine release. 
Due to ethical reasons, it was not possible to obtain pre-adipocytes from the infrapatellar fat 
pad (IPFP). The following experiments were mostly done with the cells isolated from the 
subcutaneous fat tissue of the patient with Simpson-Golabi-Behmel syndrome (SGBS, see 
chapter 1.4, 2.2). To avoid the potential differences in behavior of the cells after irradiation, 
additional experiments with the primary human adipocytes were performed.  
3.4.1 Proliferation and differentiation of human (pre)adipocytes 
In order to assess the radiation response of adipocytes, first, the proliferation capacity of 
irradiated pre-adipocytes compared to the unirradiated cells was evaluated. Radiation-
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induced changes were monitored in primary- and in SGBS-pre-adipocytes over 21 days. As 
shown in the Fig. 3.17, the proliferation pattern of SGBS-pre-adipocytes was very similar to 
that of primary pre-adipocytes. It was established that the cell number of irradiated pre-
adipocytes was in both cases dose dependent reduced (Fig. 3.17). The difference in the cell 
number between irradiated cells and controls was detectable from day 12 on for both the 
primary cells (Fig. 3.17A) and the SGBS-cells (Fig. 3.17B). It is notable that the irradiation 
with 0.5 Gy reduced the cell number of SGBS-cells compared to control, while did not affect 
that of primary cells. The strongly reduced cell number of pre-adipocytes exposed to 2 Gy X-
rays was observed over the whole observation period in both cell types. No progress in the 
proliferation of the cells irradiated with 10 Gy was determined. 
 
Fig. 3.17 Proliferation of human pre-adipocytes after X-ray irradiation. (A) Human primary subcutaneous pre-
adipocytes and (B) SGBS pre-adipocytes were irradiated with 0.5, 2 and 10 Gy X-rays and cultivated over 21 days. 
Cell counting was performed at indicated days. Mean, SEM. N=3  
To evaluate whether the ionizing radiation affects differentiation process from pre-adipocytes 
to adipocytes, the differentiation was initiated in the pre-adipocytes immediately after 
exposure to X-rays. For the primary cells, the amount of accumulated triglycerides was 
measured in the irradiated cells and compared to control. Thereby, a small dose dependent 
trend towards an increase of fat accumulation was detected 10 days after irradiation. This was 
also confirmed by triglyceride measurements on day 20. Furthermore, the fat amount was 
significantly higher in the cells exposed to the 10 Gy of X-rays compared to the controls (Fig. 
3.18). To evaluate the effect of radiation on differentiation of SGSB-cells, these were 
cultivated on the chamber-slides and stained with Oil Red O and DAPI at indicated days. 
Then, the number of differentiated (Oil Red O+, DAPI+) cells and the total cell number 
(DAPI+) of one visual field were determined. In total, seven vision fields per slide were 
counted. The differentiation rate was calculated as a ratio of differentiated cells to the total 
cell number. As shown in the Fig. 3.19, the unirradiated SGBS-cells reached the 
differentiation rate about 60% already on day 7 after differentiation start and this rose to 80% 
until day 21. Further cultivation of cells did not result in an increase of differentiation rate 
and the curve achieved a plateau (Fig. 3.19). With regard to radiation effects on the 
differentiation process of SGBS-cells, a slight dose-dependent decrease of the differentiation 
rate was observed on day 7. However, this effect became weaker in the course of further 
cultivation. On day 21, the difference between unirradiated SGBS-cells and those exposed to 
10 Gy X-rays was about 6%. 
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Fig. 3.18 Effect of X-ray irradiation on adipocyte differentiation. The quantification of triglyceride accumulation 
was performed in human primary subcutaneous adipocytes on day 10 and 20 after irradiation with X-rays. Boxplots 
show the median, Tukey whiskers (median ± 1.5 times interquartile range) and mean (+). N=4, *p ≤ 0.05, two-tailed 
t-test 
 
 
Fig. 3.19 Effect of X-ray irradiation on differentiation of SGBS-adipocytes. SGBS pre-adipocytes were irradiated 
with 0.5, 2 and 10 Gy X-rays and cultivated over 28 days. Differentiation rate was calculated at indicated days as a 
proportion between the differentiated and undifferentiated cells. Mean, SEM. N=3 
3.4.2 Adipokine release and gene expression analysis of the adipogenic specific 
markers 
In order to further investigate the impact of ionizing radiation on differentiation process of 
adipocytes, the release of adipokines was evaluated. For the primary adipocytes, the amount 
of adipokines was determined in cell supernatants 10 and 20 days after irradiation (medium 
change was not performed). Fig. 3.20A-B indicates progress in the released levels of leptin 
and adiponectin between 10 and 20 days, but irrespective of irradiation. With respect to the 
release of visfatin, the measured amount was under the detection limit 10 days after the start 
of differentiation and has dramatically increased until day 20. Moreover, cells exposed to 10 
Gy X-rays exhibited a higher, even if not statistically significant, visfatin concentration than 
unirradiated cells (Fig. 3.20C). 
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For SGBS-cells, the amount of adipokines was measured in cell supernatants at indicated days 
24 h after medium was changed. The levels of adiponectin and leptin were below the 
detection limit of ELISA Kits (1 ng/ml for leptin; 2 ng/ml for adiponectin). In view of very low 
amounts of these adipokines in cell supernatants of the primary adipocytes even after 10 
cultivation days without medium change, this was expected. In contrast, visfatin 
concentrations were determined over the whole cultivation period from day 0 on (Fig. 3.21). 
These data indicate that SGBS-pre-adipocytes can release visfatin at the early stages of 
differentiation, which is not the case for primary pre-adipocytes. Owing to strong fluctuations 
between experiments, the radiation-mediated changes in visfatin release could not be 
recognized (Fig. 3.21B). Since the radiation-induced changes in the adipokine production by 
SGBS-adipocytes remained unclear due to variations in the release, the gene expression 
analysis was performed. Albeit the measured level of adiponectin expression was also under 
detection limit, the gene expression of leptin and visfatin expression could be evaluated. As 
shown in the Fig. 3.22, SGBS-adipocytes exhibit a trend to a dose dependent reduction of 
visfatin expression (Fig. 3.22 B), while for leptin expression no significant changes or trends 
were observed (Fig. 3.22A). The analysis of further adipogenic genes also reveals slight trends 
towards a reduced expression level of intermediate (PPARγ and C/EBPß, Fig. 3.23A,B) and 
late (C/EBPα, Fig. 3.23C) differentiation markers. Since the ability for differentiation 
depends, in particular, on the expression of these genes, the radiation-induced changes may 
have a crucial role for adipocyte development. 
Fig. 3.20 Effect of X-ray irradiation on the adipokine release by human primary adipocytes. Human primary 
subcutaneous pre-adipocytes were irradiated with 0.5, 2 and 10 Gy of X-rays and differentiation was initiated. Cell 
supernatants were collected on day 10 and 20 after irradiation and amount of (A) leptin, (B) adiponectin and (C) 
visfatin were measured using ELISA assay. Boxplots show the median, Tukey whiskers (median ± 1.5 times 
interquartile range) and mean (+). N=4 
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Fig. 3.21 Effect of X-ray irradiation on the visfatin release by SGBS-adipocytes. SGBS-pre-adipocytes were 
irradiated with 0.5, 2 and 10 Gy of X-rays and differentiation was initiated. Amount of visfatin in (A) unirradiated 
SGBS-cells (control) and (B) irradiated SGBS-cells was measured at the indicated days using ELISA assay. Mean, SEM. 
N=3 
Fig. 3.22 Gene expression of adipokines leptin and visfatin in SGBS-adipocytes. SGBS-pre-adipocytes were 
irradiated with 0.5, 2 and 10 Gy of X-rays and differentiation was initiated. Expression of (A) Leptin and (B) Visfatin 
was analyzed at indicated days using qPCR. The data are normalized to GAPDH gene expression and to the gene 
expression on day 10 (for leptin) and on day 0 (for visfatin). Mean, SEM. N=3 
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Fig. 3.23 Gene expression of selected differentiation markers in SGBS-adipocytes. SGBS-pre-adipocytes were 
irradiated with 0.5, 2 and 10 Gy of X-rays and differentiation was initiated. Gene expression of (A) PPARγ, (B) 
C/EBPß and (C) C/EBPα was analyzed at indicated days using qPCR. The data are normalized to GAPDH gene 
expression and to the gene expression on day 0 (for PPARγ and C/EBPß) and on day 5 (for C/EBPα). Mean, SEM. 
N=3 
3.4.3 Release of pro-inflammatory cytokines during differentiation 
Besides other cell types of adipose tissue, adipocytes are known to produce TNFα, IL-6 and 
other pro-inflammatory cytokines [50], [165]. To determine whether ionizing radiation 
influences the cytokine release by adipocytes, the IL-6 and IL-8 levels were measured in cell 
supernatants of primary adipocytes and SGBS-cells following irradiation.  
The levels of both cytokines were not significantly changed in cell supernatants of primary 
adipocytes collected 10 and 20 days after initiation of differentiation (medium change was 
not performed during cultivation) (Fig. 3.24). Thus, the mean level of IL-6 in the unirradiated 
cells was 95.2 ± 23 pg/104 cells on day 10 and 114.5 ± 15.3 pg/104 cells on day 20. Only the 
cells exposed to 10 Gy X-rays showed a slightly enhanced concentration of IL-6 (166.65 ± 
27.8 pg/104 cells) 20 days after irradiation. Similar, no differences in the IL-8 levels of the 
controls between 10 and 20 days (126.7 ± 56.8 pg/104 cells and 173.7 ± 84.8 pg/104 cells, 
respectively) were observed. The slightly increased amounts of IL-8 were released by the cells 
exposed to higher doses of radiation (2 and 10 Gy).  
The analysis of cytokine release by SGBS-adipocytes over 28 days indicated that the 
concentrations of IL-6 as well as IL-8 were decreasing in the course of differentiation (Fig. 
3.25). It was therefore established that the SGBS-pre-adipocytes have more pronounced pro-
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inflammatory profile than mature adipocytes. No apparent changes in the cytokine release of 
irradiated cells were seen when compared to the controls.  
In addition, release of TNFα by primary adipocytes and SGBS-cells was investigated. However, 
the cytokine levels in either case were below the detection limit. 
Fig. 3.24 Effect of X-ray irradiation on the release of IL-6 and IL-8 by human primary adipocytes. Human primary 
subcutaneous pre-adipocytes were irradiated with 0.5, 2 and 10 Gy of X-rays and differentiation was initiated. Cell 
supernatants were collected on day 10 and 20 after irradiation and amount of (A) IL-6 and (B) IL-8 and were 
measured using ELISA assay. Boxplots show the median, Tukey whiskers (median ± 1.5 times interquartile range) 
and mean (+). N=4 
Fig. 3.25 Effect of X-ray irradiation on the IL-6 and IL-8 release by SGBS-adipocytes. SGBS-pre-adipocytes were 
irradiated with 0.5, 2 and 10 Gy of X-rays and differentiation was initiated. Amounts of (A-B) IL-6 and (C-D) IL-8 
were measured at the indicated days using ELISA assay. (A) and (C) indicate release of IL-6 and IL-8 in unirradiated 
SGBS-cells. Mean, SEM. N=3 
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4 Discussion 
In the present thesis, the impact of ionizing radiation on factors related to the changes in bone 
metabolism of patients with muskuloskeletal disoreders (MSD) was investigated. The special 
focus was set on adipokines, mostly secreted by adipocytes, which are known to contribute to 
the inflammation processes in the joint. Considering the predominantly pro-inflammatory 
properties of adipokines in rheumatoid arthritis (RA) and osteoarthritis (OA), and potential 
anti-inflammatory effects of low-dose ionizing irradiation, it was hypothesized that low-dose 
radiation inhibits the adipokine-induced inflammation in the joints of patients with MSD. To 
verify this hypothesis, the circulating levels of adipokines in patients with MSD after serial 
radon spa therapy were investigated. Furthermore, the radiation-mediated changes in the 
response of synovial fibroblasts to the adipokine treatment were examined in vitro. Thereby, 
synovial fibroblasts isolated from patients with RA (RASF) and from healthy donors (NSF) 
were used. In addition, it was assessed whether ionizing radiation influences the adipocyte 
development with regard to their differentiation and concomitant release of adipokines.  
It should be noted that low doses of X-rays (photons) and alpha particles (radon exposure) 
that are used for the treatment of chronic inflammatory diseases are not in the same range. 
Accordingly, for in vitro experiments, doses of 0.5-10 Gy of X-ray were used, corresponding to 
the single or total doses applied during photon low-dose radiation therapy. For radon, the 
estimated total doses that patients receive during a radon treatment are given as effective 
doses, and are three orders of magnitude lower, ranging from 0.05 mSv to 2 mSv. 
4.1 Impact of radon treatment on the adipokine serum levels of patients   
with musculoskeletal diseases (RAD-ON01) 
Musculoskeletal diseases (MSD) are usually associated with chronic inflammation, which is 
accompanied by reduced mobility and pain. Elevated levels of various pro-inflammatory 
cytokines, joint destructive enzymes and adipokines were detected in serum and synovial fluid 
of patients with MSD [166], [167]. Adipokines, which are to a large extent secreted by 
adipose tissue, contribute to the inflammation process in the joint by inducing IL-6, IL-8 and 
MMP-1 in RA synovial fibroblasts [96], [163]. This in turn enhances the expression of RANKL, 
leading to an imbalanced OPG/RANKL ratio, the activation of bone destructive cells – 
osteoclasts, and finally to cartilage degradation and bone erosion [35], [168]. 
The objective of this part of the work was to assess whether radon treatment has an influence 
on the circulating levels of adipokines in patients suffering from MSD. The intension is to 
contribute with the obtained results to a better understanding of the pain-relieving and anti-
inflammatory effects of radon therapy. In the framework of the RAD-ON01 study, the blood 
samples of 100 patients were taken prior to and in regular intervals after the start of the 
radon treatment (6, 12, 18, and 30 weeks after the first radon bath). The patients did not 
receive any anti-inflammatory drugs during the therapy and were examined by a medical 
doctor at indicated time points to measure pain and vascular parameters [140]. In the scope 
of this thesis, adipokine levels were measured in the serum of patients [169]. 
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The main focus was set on the adipokines visfatin, adiponectin, leptin and resistin, as there is 
growing evidence that these adipokines play an important role in the development of 
degenerative joint diseases [101], [170]. Although many studies suggest the adipokines as the 
novel therapeutic targets, little is known about potential therapeutic actions. However, some 
studies showed that it may be possible to reduce adipokine serum levels using nonsteroidal 
anti-inflammatory drugs [171] or TNFα-inhibitors [120]. Popa et al, for instance, showed the 
significant reduction of adiponectin levels in serum of RA patients treated with TNFα-inhibitor 
infliximab, but only in patients, who additionally took the stable dosage of corticosteroids 
[172]. Administration of infliximab was also shown to decrease serum level of resistin in 
patients with RA [120]. In the present study, the effect of low-dose radon treatment on the 
circulating levels of adipokines in a large group of patients with MSD was shown for the first 
time.  
In the present work, no significant changes for adiponectin, leptin and resistin (Fig. 3.2A, 
3.3A, 3.4A) were observed. There are only two studies, published by Suman et al, providing 
information on the effects of ionizing radiation on the serum levels of adipokines. In these 
studies, levels of leptin and adiponectin were measured in serum of mice, irradiated either 
with heavy ions (1.6 Gy, 56Fe, whole-body) or with γ-rays (2 Gy, 137Cs, whole-body). While the 
adiponectin serum level remained unchanged, the serum concentration of leptin was found in 
both cases to be significantly higher 2 and 12 months after irradiation [173], [174]. The 
authors suggested that upregulation of leptin together with insulin-like growth factor 1 (IGF-
1) could result in the activation of PI3K/Akt and JAK2 pathways, contributing to the 
pathophysiological consequences such as premature senescence and metabolic alterations 
[173], [174]. Considering the different dose and type of radiation as well as differences 
between species, it is not possible to compare the results presented here with that from 
Suman et al. However, radiation-induced increase of leptin, which is tightly associated with 
insulin metabolism, may represent an important link between radiotherapy and development 
of obesity in cancer survivors [175].  
Since many functions of adipose tissue are co-regulated by gender and other systemic factors 
[176], the relationship between adipokine levels and age, gender and pain duration was 
analyzed in the work presented here. No correlations were found between serum levels of 
adiponectin, leptin and resistin and age of patients. With regard to gender-related differences, 
the mean levels of adiponectin and leptin were significantly lower in men than in women, 
whereas the mean level of resistin was comparable for both men and women (Fig. 3.2B, 3.3B, 
3.4B). Although these data are in line with the other studies [87], [88], [177], the reason for 
the gender-related differences is not completely understood. According to Hellstroem et al 
and Ahonen et al, they may be caused by at least two different mechanisms. First, the fat 
tissue distribution differs between men and women; women have more subcutaneous fat 
tissue than men. Since adiponectin is mainly produced by the subcutaneous adipocytes, this 
would explain the difference in the serum levels [178]. Second, women may have a higher 
production rate of adipokines than men due to different hormone levels [177]. In addition, 
the results of the present work revealed no significant correlations between serum levels of 
adiponectin, leptin and resistin and pain duration, indicated by patients. 
Since the expression of visfatin is highly increased during inflammation and correlates 
positively with several disease markers in patients with MSD [86], [93], [94] as well as in a 
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collagen-induced arthritis (CIA) mouse model [179], it is considered as a novel biomarker in 
chronic inflammatory diseases, including RA [84], [158], [180]. The ability of visfatin to 
induce a variety of pro-inflammatory and matrix-degrading factors in RASF and monocytes 
argues for its involvement in the pathogenesis of RA and other MSD [11], [96], [99]. In the 
present work it was found that the serum levels of visfatin were significantly reduced after 
radon therapy compared to baseline levels. Decrease of approximately 50 percent was 
detected already 12 weeks after therapy start, and was even more pronounced at the end of 
follow-up period (30 weeks) (Fig. 3.1A). This decrease was similar to the reduction of visfatin 
concentration, detected by Sglunda et al in serum of RA patients 3 months after the treatment 
with conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) [161], 
[169]. Furthermore, the authors demonstrated that a decrease in circulating visfatin predicted 
a decrease of disease activity after treatment, as assessed by disease activity score (DAS 28) 
[161]. The DAS 28 is considered as a quantitative assessment of disease activity and included, 
inter alia, pressure point measurements to evaluate pain and assessment of disease activity by 
patient, which is often based on the pain sensitivity. Besides the study of Sglunda et al, 
positive correlations of visfatin levels with osteoarthritic pain were reported by Bas et al 
[181]. Also in some other studies high visfatin levels were associated with pain and 
radiographic join damage [93], [182]. Therefore, the association between visfatin 
concentration and pain duration, shown in this thesis (Fig. 3.1D), provides an additional 
important indication for the existing relationship between pain and increased visfatin 
concentration in patients with MSD. Moreover, a positive correlation between serum 
concentrations of visfatin and pain perception, evaluated with the visual analog pain scale 
(VAS) in the framework of RAD-ON01 study [140], was found in the present work (Fig. 4.1). 
Although VAS is a scale for the measurement of subjective pain feeling, it is a required part of 
DAS 28 score and is frequently used in the pain treatment [183]. Thus, considering the long-
lasting pain reduction for the majority of patients enrolled in the RAD-ON01 study [140], and 
the relationship between visfatin concentration and perception of pain duration (Fig. 3.1D) 
and intensity (Fig. 4.1), the decreased circulating visfatin levels after radon treatment could 
be related to the decrease of disease activity observed in the patients of this study. 
 
Fig. 4.1 Correlation analysis between VAS pain score and serum visfatin concentrations in patients with MSD 
before and after radon treatment [169]. N=44, Spearman’s correlation analysis r=0.1798, *p ≤ 0.05 
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Furthermore, in the present work the serum levels of visfatin were higher in females than in 
males, but no age-related changes were detected (Fig. 3.1). The data about gender-dependent 
differences in the serum visfatin level are contradictory. While some studies reported that the 
visfatin level does not differ between genders [184], other studies demonstrated higher 
circulating concentrations of visfatin in women than in men [185].  
Apart from this, Busso et al verified the key role of visfatin in RA by showing that inhibition of 
visfatin with a pharmacological substance APO866 leads to the significantly attenuated 
inflammation, reduced cartilage damage and disease severity in CIA mouse model [91], 
[179]. Radon therapy was also shown to decrease the serum levels of TNFα and RANKL, 
powerful promoters of inflammation and bone resorption, in patients with RA and OA [141].  
In addition, it has been observed that RA and OA are associated with several components of 
metabolic syndrome, such as insulin resistance or changes in fat distribution and adipokine 
profile [47], [186]. Each of these components is an independent risk factor for developing 
cardiovascular diseases. Since MSD are closely associated with accelerated atherosclerosis 
[11], [40] and there is growing clinical evidence supporting a role of visfatin in development 
of cardiovascular diseases [97], it can be assumed that visfatin and other adipokines are 
involved in RA-associated metabolic syndrome. Novel treatment possibilities, which improve 
insulin sensitivity and normalize the adipokine levels in MSD patients, are therefore urgently 
needed. Also based on this, low-dose radon treatment could provide a therapeutic option for 
the therapy of RA and other musculoskeletal diseases.  
4.2 Radiation response of adipokine-treated synovial fibroblasts 
Besides chronic inflammation, musculoskeletal diseases such as RA and OA are characterized 
by prominent cartilage destruction and bone erosion. Rheumatoid arthritis synovial fibroblasts 
(RASF) are the dominant cell type, which promotes degenerative changes in the joint [18], 
[83]. In healthy joints, the main functions of SF are the maintenance of matrix remodeling 
and the supply of joint cavity and cartilage with the essential nourishing proteins and 
molecules [29], [80], [187]. In the course of RA, synovial fibroblasts acquire an aggressive 
phenotype, triggered by inflammation. Due to their invasive growth capacity, reduced ability 
to undergo apoptosis and high migration potential, RASF are often compared to cancer cells 
[32], [188].  
In addition, RASF are known to produce a variety of pro-inflammatory cytokines, matrix-
degrading enzymes and osteoclasts-activating factors, actively contributing to inflammation 
and destruction of cartilage and bone. [37], [188]. Cytokines such as IL-6, IL-8, MCP-1, 
together with other factors, play an important role in the self-activation of RASF as well as in 
the crosstalk between RASF and other cells in the joint. Besides cytokines, adipokines are 
known to induce the expression of pro-inflammatory and matrix-degrading factors in RASF, 
leading to perpetuation of inflammation and joint destruction [11]. Although RASF in the 
context of RA were widely investigated in the past, the activation mechanisms are not 
completely understood yet. There is also a lack of studies, clarifying the molecular differences 
between rheumatoid arthritis synovial fibroblasts (RASF) and synovial fibroblasts from 
healthy joints (NSF). Although some studies reveal significant differences between NSF and 
synovial fibroblasts from patients with osteoarthritis (OASF) [189], the latter are often used 
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as a control in the RASF investigations, while the data about NSF are rare. Due to ethical 
reasons, it is very difficult to obtain synovial fibroblasts from healthy individuals. That is why 
the knowledge about NSF is still limited.  
For the treatment of patients suffering from MSD, usually pharmacological medication is 
used. Since the diseases such as RA or OA are still considered incurable, the aim of the 
treatment with drugs is to relieve pain and to prevent progression of the disease. However, 
the results obtained in the RAD-ON01 study as well as other studies suggest that additional 
pain relief can be achieved when the patients receive low-dose radiation therapy using 
photons [133] or radon spa treatment [140], [169], [190]. Although several studies showed 
the anti-inflammatory effects of low-dose radiation in arthritic joint [134], [135], [137], the 
radiation response of synovial fibroblasts was not investigated yet.  
In the present work, in vitro examination of the effects of X-ray irradiation on NSF and RASF 
was performed. In addition, radiation-mediated changes in the adipokine-induced expression 
of inflammatory and bone destructive factors in NSF and RASF were investigated. For this 
purpose, as a first step, the response of synovial fibroblasts (NSF and RASF) to the adipokines 
adiponectin and visfatin was tested. It was found that the expression and release of pro-
inflammatory cytokines such as IL-6, IL-8 and matrix-degrading enzyme MMP-1 in synovial 
fibroblasts were strongly induced by stimulation with both adipokines (Fig. 3.7-3.9, 3.11-
3.12). In addition, a significant increase of MCP-1 expression was observed in SF after 
stimulation with visfatin, whereas after stimulation with adiponectin the level of MCP-1 
remained unchanged (Fig. 3.9, 3.12).  
Although clear differences in the release of IL-6, IL-8 and MMP-1 were observed in all samples 
after stimulation with adipokines, the statistical significance could not be reached. This is 
mostly due to the high variability between samples, which is most likely traced to 
interindividual donor differences. Furthermore, there is evidence that RASF exhibit stronger 
variability than NSF. It is important to note that the increase of all these factors in NSF was 
very similar to that in RASF, suggesting that the ability to respond to adipokine stimulation is 
not restricted to synovial fibroblasts of arthritic joints. Moreover, the basal level of these 
factors did not differ significantly between NSF and RASF. In previously published studies, an 
adiponectin- and visfatin-mediated enhancement of IL-6, IL-8 and MMP-1 in RASF was shown 
[105], [107], [186]. Similarly, it was reported that synovial fibroblasts from osteoarthritic 
joint (OASF) also respond to a stimulation with adipokines, albeit to a smaller extent than 
RASF [100], [164]. The response of NSF to adipokine stimulation was shown in this thesis for 
the first time. However, Ehling et al showed that also normal dermal fibroblasts are able to 
produce IL-6 after stimulation with adiponectin. According to this study, the capacity to 
exhibit the pro-inflammatory phenotype upon stimulation with adiponectin may be a general 
characteristic for cells of mesenchymal origin [164]. Hence, probably all synovial fibroblasts 
are able to exert pro-inflammatory properties, depending on the surrounding conditions.  
The upregulation of cytokines such as IL-6, IL-8 as well as other key mediators in destructive 
arthritis (MMP-1, RANKL) is mediated by NF-kB, which is one of the most important 
regulators of inflammatory gene expression [191], [192]. Therefore, it can be assumed that 
adiponectin and visfatin activate the NF-kB-pathway in synovial fibroblasts, leading to the 
observed increased cytokine production. However, the synthesis of cytokines seems to be very 
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specific, since the up-regulation was observed for some (IL-6, IL-8, MMP-1), but not for all 
factors, mediated by NF-kB. Neither in the present work nor in other studies [164], the pro-
inflammatory cytokines such as TNFα or IL-1ß were affected.  
MCP-1 is another important factor involved in arthritic inflammation. The increased 
production of MCP-1 by synovial fibroblasts attracts peripheral monocytes and T cells to the 
site of inflammation [44], [187], [193]. As shown in Fig. 3.9 and 3.12, visfatin caused a 
higher increase of MCP-1 in RASF compared to adiponectin. One possible reason for this 
could be the activation of different pathways by adiponectin and visfatin. Different studies 
suggest an activation of the p38 MAP kinase pathway by visfatin [180]. Moreover, Shahrara et 
al showed that inhibition of p38 MAPK dramatically reduces MCP-1 expression, which results 
in the improvement of disease severity of arthritic mice [194]. In addition, Meier et al 
reported a significant decrease of IL-6 in visfatin-stimulated RASF only after inhibition of p38-
MAPK, but not after inhibition of NF-kB signaling pathway [96]. Since also in some other 
studies the visfatin-induced upregulation of IL-6 and IL-8 was shown to be mediated by p38 
MAPK, this pathway is more likely to be activated by visfatin. Data about mechanisms 
underlying the adiponectin-induced MCP-1 production are rare. Frommer et al suggested the 
p38 MAPK and PKC pathways to be involved in adiponectin-mediated signaling. However, 
although the inhibition of p38 MAPK in RASF reduced MCP-1 secretion, the observed 
differences were not significant [100]. 
Ionizing radiation modulates inflammatory processes. On the one hand, low doses of 
radiation (< 1 Gy) are considered to attenuate inflammatory processes and are therefore used 
for the therapy of MSD. On the other hand, high doses (> 1 Gy), applied for the cancer 
treatment, are able to initiate local and systemic inflammatory reactions [138]. Based on the 
results of the RAD-ON01 study, it was assumed that low-dose radiation can reduce the 
adipokine-induced production of pro-inflammatory cytokines by synovial fibroblasts.  
To gain insights into the radiation response of synovial fibroblasts, the cells were exposed to 
different doses of X-rays (0.5, 2, 10 Gy). The proliferation capacity of synovial fibroblasts after 
X-ray irradiation was dose-dependently reduced. Furthermore, the results revealed that NSF 
are more sensitive to radiation exposure than RASF. Exposure to 0.5 Gy X-rays did not 
significantly affect the proliferation of NSF, while irradiation with 2 Gy reduced the cell 
growth by about 40 percent. The exposure to 10 Gy X-rays completely inhibited the 
proliferation of NSF (Fig. 3.5A). At present, it is the first investigation on the radiation 
response of synovial fibroblasts. However, similar radiation-mediated changes were detected 
in the proliferation of other cell types, such as osteoblasts or endothelial cells [195], [196]. A 
delayed proliferation is associated with the time needed for DNA repair. Depending on the 
severity of the radiation-induced DNA damage, the possible consequences for the cell include 
DNA repair, senescence, cell cycle arrest or apoptosis [197]. Thus, it can be assumed that 
decelerated proliferation after 0.5 and 2 Gy of X-rays is associated with DNA repair, while 
irradiation with 10 Gy most likely induced a senescence program in the cells. By contrast, 
RASF showed a higher resistance upon irradiation. Even the exposure to 10 Gy X-rays did not 
completely suppress the growth of the cells (Fig. 3.5B).  
In addition, both cell types were incapable to form the colonies after irradiation. Moreover, 
RASF did not form colonies, even if the cells were not irradiated. However, very low plating 
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efficiencies of primary cells are well known and are probably caused by the lack of cell-cell 
contacts at low cell density, which is required for the clonogenic survival assay [198].  
To further elucidate radiation-mediated changes in synovial fibroblasts, the production of 
major pro-inflammatory cytokines was investigated. Although in various cell types the 
changes in IL-6 and IL-8 expression were shown already a few hours after irradiation [199], 
[200], in the present study the cytokine production by unstimulated synovial fibroblasts was 
not affected by irradiation. Even the exposure to 10 Gy X-rays did not significantly change IL-
6, IL-8 and MCP-1 levels of both NSF and RASF (Fig. 3.13 – 3.16). Similarly, neither NSF nor 
RASF showed the changes of MMP-1 synthesis after irradiation. Since the measurements were 
performed at the one time point only (48 h), it cannot be ruled out that changes in the 
cytokine response occur later.  
Nevertheless, the treatment with adipokines changed the reaction of the cells to irradiation as 
can be seen on the changed cytokine production by irradiated synovial fibroblasts, pretreated 
with adipokines (Fig. 3.13 – 3.16). It is worth mentioning that the release of cytokines, which 
were highly upregulated after treatment with adipokines (IL-6, IL-8 and MMP-1), was reduced 
by exposure to X-rays. However, this response was different between NSF and RASF. In the 
adipokine-stimulated NSF, the production of the pro-inflammatory factors (IL-6, IL-8, MCP-1, 
MMP-1) was either unchanged or slightly increased. By contrast, the adipokine-pretreated 
RASF showed a slight, but consistent trend towards a decrease of cytokine production. In 
addition, this effect was more pronounced in visfatin-treated RASF in comparison to 
adiponectin-treated cells. Although statistical significance could not be reached due to 
pronounced fluctuations between single experiments, each of them revealed similar trends. As 
mentioned before, it is conceivable that adiponectin and visfatin activate different signaling 
pathways. It hence appears to be likely that ionizing radiation affects both p38 MAPK and NF-
kB pathways, leading to the decreased expression of pro-inflammatory cytokines. However, 
this presumption is in conflict with a current knowledge about mentioned pathways in 
radiation response. Even though the role of p38 MAPK appears to variate between different 
cell types and stress factors, many groups reported the radiation-induced activation of this 
pathway [201], [202]. Similarly, the NF-kB activation in response to radiation is well known.  
In previous studies, the ability of visfatin to induce reactive oxygen species (ROS) was shown. 
For example, Kim et al showed that visfatin enhances the expression of adhesions molecules 
ICAM-1 and VCAM-1 in endothelial cells through ROS-dependent activation of NF-kB 
pathway [203]. Low-dose radiation was shown to reduce significantly ROS level in stimulated 
murine macrophages [204]. However, data about the relationship between low-dose radiation 
and ROS level are contradictory. Thus, Large et al showed an elevated level of ROS in 
endothelial cell line following 0.5 Gy X-rays irradiation. These discrepancies suggest that the 
effects of low-dose radiation is dependent on the cell type or cellular environment, leading to 
various consequences [154]. Although there are no studies about ROS measurement in 
synovial fibroblasts, visfatin-induced expression of adhesion molecules is known [96]. Thus, it 
could be assumed that visfatin enhances the ROS level in synovial fibroblasts, leading to the 
activation of NF-kB and p38 MAPK pathways and finally to the overexpression of adhesion 
molecules and pro-inflammatory cytokines (Fig. 4.2). Low-dose radiation in turn could reduce 
the level of ROS and therefore attenuate their effect. However, the direct activation of p38 
MAPK and NF-kB by visfatin cannot be ruled out. Therefore, it should be clarified whether 
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low-dose radiation affects a visfatin-induced production of ROS or rather NF-kB/p38 MAPK 
pathways directly.  
 
Fig. 4.2 Proposed signalling pathways and involvement of reactive oxygen species (ROS) in visfatin-mediated 
cytokine overexpression by RASF 
Taken together, in the work presented here it was shown that the adipokines adiponectin and 
visfatin strongly induced the production of IL-6, IL-8, MCP-1 and MMP-1 in both NSF and 
RASF. Moreover, the impact of ionizing radiation on the adipokine-induced release of pro-
inflammatory factors by synovial fibroblasts was shown for the first time. Thereby, it was 
determined that radiation can reduce the levels of IL-6, IL-8, MMP-1 and MCP-1 in the 
adipokine-treated RASF, but not in NSF. There is thus a need to clarify the molecular 
differences between NSF and RASF. In addition, it was found that irradiation did not affect 
the untreated synovial fibroblasts with regard to cytokine production. Therefore, the signaling 
pathways activated by adiponectin and visfatin should be investigated in more detail. The 
most likely candidates are, as mentioned before, p38 MAPK and NF-kB. It is also possible that 
part of the effects could be a consequence of increased oxidative stress caused by visfatin. It 
would therefore be reasonable to investigate the adipokine-mediated ROS production by 
synovial fibroblasts and the influence of ionizing radiation on it.  
4.3 Radiation-mediated changes in human (pre)adipocytes during 
differentiation 
The infrapatellar fat pad (IPFP) is a special depot of adipose tissue located in the knee joint, 
close to synovial layers and cartilage. Considering its location and the pro-inflammatory 
properties of adipose tissue (see chapter 1.4), the involvement of IPFP in the pathogenesis of 
degenerative joint diseases such as RA or OA is conceivable. Although it is assumed that the 
enhanced adipokine levels, detected in synovial fluid of patients with MSD [158], [205], 
originate from IPFP, only little is known about its role in the physiological and pathological 
processes. 
In view of the important role of radiation therapy, the number of studies on radiation 
response of different tissues and cell types is constantly increasing. However, there are almost 
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no data available about effects of radiation exposure on adipose tissue or adipocytes. So far, 
two studies were published, which nonetheless provide controversial information. Poglio et al 
reported the loss of adipose tissue weight in mice after irradiation (7-10 Gy/137Cs, whole-body 
irradiation) [206]. By contrast, Jo et al showed two times higher weights of adipose tissue in 
irradiated mice (5 Gy/137Cs, whole-body irradiation) than in unirradiated mice [207]. Such 
differences could probably be related to the different time points, which were analyzed. Thus, 
in the study of Poglio et al the results are shown 7 days after irradiation and in the study of Jo 
et al – 8 months after irradiation. Nevertheless, both groups agreed on one point – ionizing 
radiation induces metabolic changes in the adipose tissue. Considering the lack of knowledge 
about radiation effects on adipocytes and the decrease of visfatin in serum of patients after 
low-dose radon treatment, the aim of this part of the thesis was to investigate radiation 
response of adipocytes with respect to the differentiation process and the ability to release 
adipokines. 
Due to ethical reasons, it was not possible to obtain cells from human IPFP. Therefore, in this 
study, pre-adipocytes isolated from human subcutaneous adipose tissue were used. Moreover, 
the experiments were mostly done with SGBS-pre-adipocytes, which are characterized by a 
retained ability to adipogenic differentiation [68]. In order to verify whether the observed 
radiation response of SGBS-cells reflects the physiological behavior, additional experiments 
with human primary pre-adipocytes were conducted. 
Initially, the sensitivity of pre-adipocytes to irradiation with respect to proliferation capacity 
was investigated. The results revealed that the proliferation of both SGBS- and primary pre-
adipocytes after exposure to X-rays was dose-dependently reduced. However, only high doses 
of X-rays (2 and 10 Gy) caused a significant decrease of the cell number. Moreover, 
irradiation with 10 Gy completely inhibited the cell growth of SGBS-cells as well as of primary 
pre-adipocytes. Pre-adipocytes arise from mesenchymal stem cells and their proliferation 
pattern after irradiation was very similar to that of other cells of mesenchymal origin or 
mesenchymal stem cells itself [196], [208]. This observation is also in line with Jeong et al, 
who reported a significant decrease in the proliferation of adipose-derived stem cells obtained 
after irradiation of the pig [209]. 
To evaluate the radiation effects on differentiation process of adipocytes, the cells were 
irradiated as pre-adipocytes and then differentiation was initiated. The changes were 
monitored over a period of 20 - 28 days. The most prominent adipogenic marker is the ability 
to accumulate lipids. Therefore, the triglyceride accumulation and the differentiation rate 
during differentiation were examined in SGBS- and primary cells. The results revealed that 
primary adipocytes tend to increased lipid accumulation after irradiation. Moreover, exposure 
of the pre-adipocytes to 10 Gy of X-rays resulted in a significantly higher lipid content on day 
20 after irradiation compared to unirradiated cells (Fig. 3.18). This is in line with Jo et al, 
who also reported increased size of irradiated adipocytes compared to controls [207]. 
Furthermore, some other studies considered the obesity development in the childhood 
leukemia survivors as a late effect of radiotherapy [210], [211]. However, although an 
increase in lipid accumulation after irradiation was detected, the differentiation rate did not 
differ between irradiated and unirradiated cells. The obtained results together with that of Jo 
et al suggest that high doses of radiation induce hypertrophy (cell size increase) rather than 
hyperplasia (cell number increase) of fat cells. At the earlier stages, however, the 
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differentiation rate was dose-dependently decreased (Fig. 3.19), which may reflect a delay of 
differentiation due to radiation-induced changes in the expression of genes responsible for 
maturation of adipocytes (Fig. 3.23).  
The development and differentiation of adipocytes is subjected to a close regulation and 
controlling by a variety of growth- and transcription factors (Fig. 1.4). According to the 
literature, the crucial transcription factors for adipocyte development are peroxisome-
proliferator-activated receptor γ (PPARγ) and CCAAT-enhancer-binding proteins (C/EBPs). 
PPARγ and C/EBPα are necessary not only for induction of adipogenesis, but also for growth 
arrest, which is required for adipocyte maturation (Fig. 1.4) [61]. Together with C/EBPß, an 
earlier adipogenic marker, these genes determine the differentiation process of adipocytes. In 
the present work, the gene expression of PPARγ, C/EBPα and C/EBPß was found to be mostly 
unaffected by irradiation. However, the observed slight trends towards reduced expression 
(Fig. 3.23) could be associated with the delay at the beginning of differentiation mentioned 
before. In the late stages of differentiation, the mature adipocytes are characterized by the 
production of highly specific markers such as leptin, adiponectin and visfatin [43]. Although 
the analysis of gene expression of the mentioned markers met a number of technical 
difficulties, a slight, albeit not significant decrease in the visfatin expression was observed 
(Fig. 3.22B). This, however, was not supported by the investigation of visfatin release.  
These results are in agreement with those published by Li et al [208] and Nicolay et al [212]. 
Both authors investigated the effects of ionizing radiation on the differentiation capacity of 
MSC, the adipocyte precursor cells. Li et al considered that irradiation with 2 and 4 Gy 
(photon radiation) did not significantly affect the differentiation process to adipocytes. 
However, for MSC exposed to 8 and 10 Gy, a reduced number of mature adipocytes was 
observed [208]. Furthermore, similar to the data presented here, Nicolay at al showed that 
expression of various adipogenic or osteogenic differentiation markers in irradiated MSC 
remained unchanged, suggesting that on transcriptional level the differentiation was not 
affected [212]. 
SGBS-cells constantly secreted visfatin during the whole observation period; however, the 
radiation-induced changes could not be established due to pronounced fluctuations (Fig. 
3.21). In contrast to visfatin, the values of adiponectin and leptin were below detection limit. 
On the one hand, this could be explained by extremely low amounts of adipokines produced 
in 24 h. On the other hand, adipokine secretion by adipocytes is highly dependent on the level 
of insulin and other hormones [114]. Since the cells were starved in supplement-free medium 
24 h prior to supernatant collection to avoid a contamination by adipokines from serum, it 
can be assumed that the cells had downregulated the adipokine production as a response to 
this stress.  
For primary adipocytes, the release of adipokines was measured 10 and 20 days after 
irradiation without starvation of the cells (Fig. 3.20). The concentrations of adiponectin and 
leptin were higher on day 20 compared to day 10, which is explained by an increased 
adipokine secretion in the course of differentiation. However, no radiation-induced changes 
were observed. Only the cells exposed to 10 Gy X-rays showed a tendency towards higher 
adipokine release. Interestingly, the visfatin level was below the detection limit in the 
supernatants of primary adipocytes on day 10 and has dramatically increased until day 20 
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(Fig. 3.20C). This is different from SGBS-cells, which permanently secreted visfatin from the 
day 0 (pre-adipocytes) on (Fig. 3.21).  
As the adipose tissue and adipocytes are also described to produce a variety of pro-
inflammatory cytokines [165], [166], [213], radiation-mediated changes in the release of IL-6 
and IL-8 during differentiation process of adipocytes were investigated. In primary adipocytes, 
the amounts of both cytokines did not differ between 10 and 20 cultivation days and were not 
significantly affected by irradiation (Fig. 3.24). Also in SGBS, the secretion of IL-6 and IL-8 
was not changed by radiation; however, a continuous decrease in the course of differentiation 
was observed for both cytokines (Fig. 3.25). This data suggests that rather pre-adipocytes 
than mature adipocytes possess the pro-inflammatory properties. It is in accordance with 
Harkins et al, who reported higher IL-6 expression in mouse pre-adipocytes than in mature 
adipocytes [214].  
Many studies suggested that adipose tissue is one of the main sources of pro-inflammatory 
cytokines. For example, Fried et al and Mohamed-Ali et al demonstrated that the adipose 
tissue releases a large amount of IL-6 [215], [216]. Moreover, Fried et al also reported that 
IL-6 was expressed to a large extent by the stromal vascular fraction (SVF) of adipose tissue; 
however, the exact cell type was not identified [216]. These data suggested that not 
adipocytes, but other cells of the adipose tissue may contribute to the enhanced concentration 
of IL-6 and IL-8 in the arthritic joint. However, it should be noted that in the present work 
and in most studies the experiments were done with subcutaneous adipose tissue or 
adipocytes. Although it has not been clarified yet whether the different fat depots have a 
different role in the physiological and pathological processes, some studies reported 
differences in the cytokine profile of different fat depots. For example, Distel et al 
demonstrated higher IL-6 release by IPFP than by subcutaneous adipose tissue [55]. Another 
example is provided by Klein-Wieringa et al, who found higher levels of IL-6, adiponectin and 
visfatin in the IPFP compared to subcutaneous fat tissue of OA patients [54]. These data 
indicate a more inflammatory phenotype of IPFP compared to other fat depots, which should 
be considered for further investigations. 
In summary, in the present work the radiation response of human primary (pre)adipocytes 
was characterized for the first time. The potential of subcutaneous preadipocytes to 
differentiate into mature adipocytes seemed to be rather radiation-resistant. Even the high 
doses of X-rays did not significantly perturb adipogenic differentiation and the ability of 
adipocytes to produce adipokines. Furthermore, the results presented here showed that SGBS-
cells exhibit mostly the same response to radiation as primary (pre)adipocytes.
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5 Summary 
In this thesis, a significant decrease of visfatin level in serum of patients after serial radon-
baths treatment of patients with MSD (RAD-ON01 study) was shown for the first time. 
Furthermore, the amounts of visfatin were found to correlate with pain duration, indicated by 
patients, and with the VAS pain score. Considering the long-lasting pain relief in patients 
participating in this study [140] and the decrease of serum-TNFα, reported by Lange et al 
[141], the obtained results indicate that low-dose radon treatment attenuates the 
inflammation process in MSD patients. Furthermore, the in vitro investigations on effects of 
radiation on adipokine-treated synovial fibroblasts (SF), performed within scope of this thesis, 
supported the in vivo data. It was shown that the adipokine stimulation induced production of 
pro-inflammatory cytokines and matrix-degrading enzymes in both healthy (NSF) and 
rheumatoid arthritis SF (RASF), indicating the ability of all SF types to obtain an aggressive 
phenotype, depending on surrounding conditions. The ionizing radiation in turn reduced the 
adiponectin- and visfatin-induced production of pro-inflammatory cytokines (IL-6, IL-8, MCP-
1) and matrix-degrading enzymes (MMP-1) in RASF.  
Furthermore, in the present thesis, the radiation response of adipocytes was investigated for 
the first time. The results revealed that neither the ability of (pre)adipocytes to differentiate 
nor to produce adipokines was affected by ionizing radiation. Even the exposure to high doses 
of radiation (10 Gy) did not significantly change the gene expression of adipogenic markers. 
These results give inside into the regulation of the adipocyte development upon stress and the 
respective response. In addition, the obtained results suggest that adipocytes are probably not 
the main source of adipokines in the arthritic joint. However, it should be clarified whether fat 
cells, derived from other adipose tissue depots (esp. IPFP), exhibit the same radiation 
response as subcutaneous adipocytes used in this work.  
To summarize the present work, the adipokines visfatin and adiponectin play an important 
role in the pathogenesis of MSD and presumably also in the RA-associated metabolic 
syndrome. Radiation exposure reduces adipokine-induced production of pro-inflammatory 
cytokines and matrix-degrading enzymes in RASF, supporting anti-inflammatory properties of 
low-dose radiation. These in vitro results are compliant with the in vivo observed decrease of 
serum visfatin levels in MSD patients after low-dose radon treatment, both indicating 
attenuation of inflammatory process in arthritic joint. Therefore, low-dose irradiation could 
provide a therapeutic option for the treatment of patients suffering from MSD. Ionizing 
radiation does not affect the differentiation process of adipocytes and their ability to produce 
adipokines, suggesting that adipocytes are not the main source of adipokines in the joint. The 
results obtained within the scope of this thesis contribute to a better understanding of the 
cellular and molecular mechanisms underlying clinical effects of low-dose radio- (LD-RT) and 
radon therapy. 
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Appendix 
Tab. A.1 Kits for molecular biological and immunological analysis 
 
 
 
Name Manufacturer 
Human Leptin ELISA Kit TecoMedical Group 
Human Leptin ELISA Kit Life Technologies 
Total Human Adiponectin ELISA TecoMedical Group 
Human Nampt (Visfatin/PBEF) ELISA Kit Adipogen 
Human Resistin ELISA Kit Adipogen 
Human sRANKL (total) ELISA BioVendor 
COMP® ELISA Immundiagnostic Systems 
Ltd. 
RayBio® Human MMP-1 ELISA Kit RayBiotech 
RayBio® Human MMP-3 ELISA Kit RayBiotech 
RayBio®Human MMP-13 ELISA Kit RayBiotech 
Human IL-6 ELISA Ready-SET-Go eBioscience 
Human IL-8 ELISA Ready-SET-Go eBioscience 
Human TNFα ELISA Ready-SET-Go eBioscience 
Human CCL2 (MCP-1) ELISA Ready-SET-Go eBioscience 
RNeasy Mini Kit Qiagen 
RevertAid First Strand cDNA Synthesis Kit Thermo Scientific 
QuantiFast SYBR Green PCR Kit Qiagen 
Hs_LEP_1_SG_QuantiTect Primer Assay Qiagen 
Hs_ADIPOQ_va.1_SG_QuantiTect Primer Assay Qiagen 
Hs_NAMPT_1_SG_QuantiTect Primer Assay Qiagen 
Hs_PPARG_1_SG_QuantiTect Primer Assay Qiagen 
Hs_CEBPA_1_SG_QuantiTect Primer Assay Qiagen 
Hs_LEPR_1_SG_QuantiTect Primer Assay Qiagen 
Hs_ADIPOR1_1_SG_QuantiTect Primer Assay Qiagen 
Hs_SLC2A1_1_SG_QuantiTect Primer Assay Qiagen 
Hs_SLC2A4_1_SG_QuantiTect Primer Assay Qiagen 
Hs_MMP3_1_SG_QuantiTect Primer Assay Qiagen 
Hs_MMP1_1_1_SG_QuantiTect Primer Assay Qiagen 
Hs_MMP13_1_SG_QuantiTect Primer Assay Qiagen 
Hs_CXCL8_1_SG_QuantiTect Primer Assay Qiagen 
Hs_IL6_1_SG_QuantiTect Primer Assay Qiagen 
Hs_CCL2_1_SG_QuantiTect Primer Assay Qiagen 
Hs_GAPDH_1_SG_QuantiTect primer Assay Qiagen 
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Tab. A.2 Chemicals 
Name Manufacturer 
2-Mercaptoethanol Sigma-Aldrich 
Acrylamid Rotiphorese 30% Roth 
AEBSF, 4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride 
Sigma-Aldrich 
APS, amonium persulfate Sigma-Aldrich 
Basal medium & growth supplement for synovial fibroblasts Cell Applications 
Biotin Sigma-Aldrich 
BSA (bovine serum albumin)  
Cortisol Sigma-Aldrich 
DAPI Serva 
Dexamethasone Sigma-Aldrich 
DMEM Merck  
DMEM/F12 Invitrogen 
DMSO (dimethyl sulfoxide) Sigma-Aldrich 
Ethanol Merck  
Fetal calf serum Biochrom AG 
Formaldehyde Merk 
Glycerol Sigma-Aldrich 
HEPES Biochrom AG 
Human insulin Sigma-Aldrich 
Human recombinant adiponectin RayBiotech 
Human recombinant visfatin BioVendor 
Human transferrin Sigma-Aldrich 
IBMX Sigma-Aldrich 
Isopropanol Roth 
L-Glutamine Biochrom AG 
Methanol Roth 
Methylene blue Roth 
Non-fat dry milk Roth 
Oil Red O Sigma-Aldrich 
Panthotenat Sigma-Aldrich 
PBS (phosphate buffered saline) Merck  
Penicillin/Streptomycin solution Invitrogen 
PGM (preadipocytes growth medium) + supplements Lonza 
Amersham ECL Prime Western Blotting Detection Reagent  GE Healthcare Life 
Sciences 
Rosiglitazone Cayman Chemicals 
Rotiquant Coomassie Brilliant Blue Dye Roth 
SDS, Sodium dodecyl sulfate Sigma-Aldrich 
Sodium chloride Merk 
Sodium orthovanadate Roth 
TEMED Sigma-Aldrich 
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Triiodothyronine (T3) Sigma-Aldrich 
Tris-Base Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Trypsin/EDTA  
 
Tab. A.3 Solutions 
Substance Concentration Solvent 
Cortisol 100 mM EtOH 
Dexamethasone 25 µM EtOH 
IBMX 250 mM DMSO 
Insulin 100 µM 10 mM HCl + 
1% BSA 
Oil Red O stock solution 3 mg/ml  Isopropanol, 
99% 
Oil red O working solution 3 ml 2 ml H2O 
Panthotenat/Biotin biotin  3.3 mM DMEM/F12 
 panthotenat  1.7 mM  
Rosiglitazone 10 mM DMSO 
Transferrin 1 mg/ml DMEM/F12 
Triiodothyronine (T3) 200 nM H2O 
 
Tab. A.4 Buffers 
Name Composition Solvent 
Blocking buffer non-fat dry milk,  5% TBST 
   
Elektrophorese buffer Tris-Base, 3.3 g H2O, 1 L 
 Glycine, 14.26 g  
 SDS, 1 g  
   
Resolving gel buffer Tris-Base, 1.5 M H2O 
 SDS, 4% w/v  
 pH=8.8  
   
RIPA lysis buffer Igepal-Buffer, 1% H2O 
 Sodium deoxycholate, 0.5%  
 Sodium fluoride, 50 mM  
 AEBSF, 1 mM  
 Aprotinin, 1 µg/ml  
 Sodium orthovanadate, 1 mM  
 SDS, 0.1%  
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Sample buffer Bromophenol blue, 0.035 g  
 Glycerol, 7 ml  
 SDS, 6 ml (10% v/v)  
 Tris-HCl, 1 ml (1 M, pH=6.7)  
 2-Mercaptoethanol, 1% v/v  
   
SDS running buffer Tris-Base, 3.03 g H2O, 1 L 
 Glycine, 71.3 g  
 SDS, 1 g  
 pH=7.2-7.4  
   
Stacking gel buffer Tris-Base, 0.5 M H2O 
 SDS, 4% w/v  
 pH=6.7  
   
TBST Tris-HCl, 1% v/v, 1 M, pH=8.3 H2O 
 NaCl, 5% v/v, 3 M  
 Tween 20, 0.05% v/v  
   
Transfer buffer Glycine, 11.27 g H2O, 800 ml 
 Tris-HCl, 20 ml  
 SDS, 1 g  
 MeOH, 20% v/v  
   
Tris-HCl Tris-Base, 1 M H2O 
 pH=8.3 (by HCl)  
 
Tab. A.5 Cell culture media 
Pre-adipocytes growth medium ( PGM2, Lonza)     
PBM2 (preadipocyte basal medium) 500 ml  
FCS    2 ml  
L-Glutamine  5 ml  
GA-1000 (gentamicin)  0.5 ml  
     
2x Adipocytes differentiation medium (Lonza)  
     
PGM2   100 ml  
Human insulin  2 ml  
Dexamethasone  0.2 ml  
IBMX   0.2 ml  
Indometacin  0.4 ml  
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SGBS media     
0F medium     
DMEM/F12   500 ml  
Panthotenat/Biotin  5 ml  
Penicillin/Streptomicin  5 ml  
     
Serum-containing medium (0F+10% FCS)  
     
0F medium   500 ml  
FCS   50 ml  
     
3 FC medium    
     
0F medium   10 ml  
Transferrin   100 µl (0.01 
mg/ml) 
Insulin   2 µl (20 nM) 
Cortisol   10 µl (100 nM) 
Triiodothyronine (T3)  10 µl (0.2 nM) 
     
Quick-Diff medium    
     
0F medium   10 ml  
Transferrin   100 µl (0.01 
mg/ml) 
Insulin   2 µl (20 nM) 
Cortisol   10 µl (100 nM) 
Triiodothyronine (T3)  10 µl (0.2 nM) 
Dexamethasone  2 µl (20 nM) 
IBMX   10 µl (250 µM) 
Rosiglitazone  2 µl (2 µM) 
     
Growth medium for RASF 0255   
     
DMEM   500 ml  
FCS (heat inactivated)  50 ml  
Penicillin/streptomycin  5 ml  
HEPES   5 ml  
     
Growth medium for NSF and RASF (Cell applications) 
Ready for use     
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Tab. A.6 Consumables 
Type Product designation  Manufacturer 
Cell culture flasks T75, T25 BD Falcon 
Cell scraper S TPP 
Chamber slides LabTek II Lab-Tek Brand 
Products 
Cover slips  Roth 
Covers for qPCR MicroAmp Applied Biosystems 
Cryo tubes 2 ml Greiner 
Multiwell plates for cell culture  TPP 
Multiwell plates for immune 
assays 
 NUNC 
Multiwell plates for qPCR MicroAmp 0,1 ml Applied Biosystems 
Petri dishes Nunclon 35 mm NUNC 
Reaction tubes 0.5-2 ml Eppendorf 
Reaction tubes 15-50 ml TPP 
Serological pipets (disposable) 2-50 ml Sarstedt 
Tips SafeSeal professional Biozym 
 
Tab. A.7 Equipment and software  
Type of device Product designation Manufacturer 
Autoclave  EL Tutthauer 
Systec 
Cell counter TC-20 Bio-Rad 
Centrifuge Multifuge 3 S-R Thermo 
Scientific 
Centrifuge Fresco 17 Thermo 
Scientific 
Dosimeter SN54 PTW Freiburg 
Electrophoresis Chamber Miniprotean Tetra System Bio-Rad 
Freezer -80 MDF-U52V Sanyo 
Ice mashine Flake-Line Wessamat 
Incubator BBD-6220 Heraeus 
Instruments 
Laminar flow bench HeraSafe Thermo 
Scientific 
Liquid N2 Tank 8213 Thermo 
Scientific 
Microscope BX61 Olympus 
Microvolume spectrometer Colibri Titertek 
Berthold 
pH meter Calimatic 766 Knick 
Photometer ELx808 Biotec 
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Scales ABJ-120-4NM Kern 
Ultrapure water system Purelab Flex ELGA/Veolia 
Ultrasonic bath Bioruptor UCD-200 Diagenode SA 
Waterbath VWB 6 VWR 
Western Blot Imaging System Fusion Peqlab 
Western Blot Transfer System Trans-Blot®Turbo™Transfer 
System 
Bio-Rad 
X-ray tube Isovolt DS1 Seifert 
 
Type of software Product designation Developer 
qPCR analysis StepOne v 2.3 Applied 
Biosystems 
Western Blot Imaging and 
Quantification 
Fusion FX Peqlab 
ELISA analysis   
Data analysis GraphPad Prism 6 GraphPad 
Software 
 
Tab. A.8 Time-dependent effect of adiponectin on IL-6 release by RASF 
Time, h 
                         IL-6, pg/ml 
                      (Mean±SD, n=3) 
 w/o adiponectin                            adiponectin 5 µg/ml 
12 0.556±0.14 0.634±0.09 
24 0.63±0.5 2.9±1.5 
36 1.9±0.65 8.25±4.6 
48 1.97±0.36 9.5±2.5 
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Effect of X-ray irradiation on adiponectin-induced expression of IL-6, IL-8, MCP-
1, MMP-1 and MMP-3 by human synovial fibroblasts 
 
Fig. A.1 Effect of X-ray irradiation on adiponectin-induced expression of IL-6, IL-8, MCP-1, MMP-1 and MMP-3 by 
human synovial fibroblasts. Synovial fibroblasts from healthy donors (NSF) and from patients with rheumatoid 
arthritis (RASF) were treated or not with 5 µg/ml adiponectin for 24h prior to irradiation with X-rays. RNA was 
isolated 24h after irradiation and gene expression analysis of IL-6 (A), IL-8 (B), MCP-1 (C), MMP-1 (D) and MMP-3 
(E) was performed. Mean, SEM. N=4 
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Effect of X-ray irradiation on visfatin-induced expression of IL-6, IL-8, MCP-1, 
MMP-1 and MMP-3 by human synovial fibroblasts 
 
Fig. A.2 Effect of X-ray irradiation on visfatin-induced expression of IL-6, IL-8, MCP-1, MMP-1 and MMP-3 by 
human synovial fibroblasts. Synovial fibroblasts from healthy donors (NSF) and from patients with rheumatoid 
arthritis (RASF) were treated or not with 5 µg/ml adiponectin for 24h prior to irradiation with X-rays. RNA was 
isolated 24h after irradiation and gene expression analysis of IL-6 (A), IL-8 (B), MCP-1 (C), MMP-1 (D) and MMP-3 
(E) was performed. Mean, SEM. N=3 
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